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Abstract 
Little attention has been brought on the lipid content and fatty acid composition directly in 
synovial fluid (SF) from joints of patients with inflammatory joint diseases. Studies indicate 
that excessive SF lipids and fatty acids found in patients with rheumatoid arthritis are mainly 
derived from blood. Several studies have demonstrated a relationship between n-6 and n-3 
polyunsaturated fatty acids (PUFA) in blood and inflammation. Generally, a high content of 
n-6 PUFA, and an increased ratio between the n-6 to n-3 PUFA increases tissue formation of 
more potent pro-inflammatory eicosanoids and cytokines, whereas an increased content of n-3 
long chain PUFA (LCPUFA), may have anti-inflammatory effects. Little is known about 
these fatty acids with respect to effects in the actual site of inflammation and joint destruction. 
 
We have performed a cross-sectional study of synovial fluid (SF) from 86 patients with 
various inflammatory joint diseases, including rheumatoid arthritis (RA), psoriatic arthritis 
(PsA), reactive arthritis (ReA), and ankylosing spondylitis (AS). The three latter diseases are 
all included in the main group of diseases, the spondyloarthropaties (SpA). The SF n-6 and n-
3 PUFA levels, and the ratios between them, were correlated to the specific inflammatory 
markers, i.e C-reactive protein (CRP) in serum, and interleukin (IL)-6 and IL-12 in SF. There 
were found significant correlations of n-6 and n-3 PUFA levels, and ratios between them, to 
levels of inflammatory markers in SF, which included the patient groups with chronic 
inflammatory joint diseases, i.e the RA, PsA and AS groups. The correlations included most 
frequently positive correlation of n-6 arachadonic acid (AA) precursors, including linoleic 
acid (LA) and dihomo--linolenic acid (DGLA), to levels of IL-6. 
 
The levels of inflammatory markers (serum CRP, SF IL-6 and IL-12) and the correlation 
between them, and the genereal SF fatty acid composition were also studied in the same 
patients. There were significantly higher levels of serum CRP in RA patients and AS 
compared with the PsA group. No differences were found concerning the levels of IL-6 in SF 
between groups, which represented the most abundant cytokine in SF. As for levels of IL-12, 
there were found significantly higher levels of the cytokine in SF from RA patients as 
compared with PsA group and the SpA main group. From the correlation of inflammatory 
markers, a significant weakly negative correlation between SF IL-12 and IL-6 in RA patients 
was found. Further, significant weakly positive correlations between serum CRP and SF IL-6 
in all patients and the SpA group were found. Approximately half of the fatty acid 
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composition in SF of all patients constitutes of PUFA, mostly n-6, whereas the other half is 
divided nearly equally between saturated fatty acids (SFA) and monounsaturated fatty acids 
(MUFA).  Significantly differences were only found between the RA and AS subgroup or 
more frequently SpA main group. All statistically significant differences were seen between 
the n-6 and n-3 PUFA levels. The RA group had generally higher content of n-3 fatty acids 
contributing to a lower n-6 to n-3 ratio.                       
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I. Introduction 
BACKGROUND 
The human diet has been represented by a hunter and gatherer lifestyle since the human 
emergence 1.7 million years ago. However, after the Agricultural evolution over the past 
10 000 years, major changes of the Western diet has appeared, and particularly during the 
Industrial period the last 100 years or so. Among others, the ratio of n-6 to n-3 
polyunsaturated fatty acids (PUFA) has increased notably, particular due to increased use of 
cheap bulkavailable n-6 PUFA rich plant oils (Simopoulos, 2002a). Various lipids are a 
significant substance of the body tissues, e.g adipose tissue and cell membranes, and a high 
dietary intake of n-6 to n-3 PUFA is reflected in blood and various tissues (Simopoulos, 
2002b). Studies indicate that n-6 and n-3 PUFA generally have different immunomodulatory 
activities. A high content of n-6 PUFA, and an increased ratio between the n-6 to n-3 PUFA 
increases tissue formation of more potent pro-inflammatory eicosanoids and cytokines, 
whereas an increased content of long chain n-3 PUFA, may have anti-inflammatory effects 
(James et al., 2003; Grimble & Tappia, 1998). Further, pathogenesis of many diseases, 
including inflammatory joint diseases, have been associated with these proinflammatory 
mediators and a physiological influence of an increased dietary and thus tissue ratio of n-6 to 
n-3 PUFA (Simopoulos, 2002a; Adam, 2003; James et al., 2003). On the contrary, n-3 PUFA 
supplementation may improve clinical disease outcome (Goldberg & Katz, 2007). Studies 
show that lipids and fatty acids in synovial fluid (SF) are mainly blood-derived (Prete et al., 
1995; Navarro et al., 2000). However, little attention has been given towards the lipid content 
and fatty acid composition directly in SF from joints of patients with inflammatory joint 
diseases (Wise et al., 1987), despite local joint inflammation resulting in pain and swelling 
(Cleland et al., 2003). Generally, the literature in this field concerns Rheumatoid arthritis 
(RA), whereas there is little knowledge about the spondyloarthropaties (SpA) (Cleland et al., 
2003; Prete et al., 1995; Navarro et al., 2000). Analyses of SF from patients with RA showed 
an altered lipid composition and lipoprotein pattern, as well as a general increased content of 
lipids (Prete et al., 1995; Bole, 1962). A decrease of n-3 PUFA in both plasma and SF of 
inflamed joints from RA patients is also reported (Navarro et al., 2000). Further, elevated 
levels of specific pro-inflammatory cytokines in both serum and SF in RA patients have been 
found, which are involved in tissue destruction in inflammatory diseases (Ribbens et al., 
2000; Punzi et al., 2002; Cronstein, 2007).  
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1.1 AIMS OF THE STUDY  
Certain n-6 and n-3 PUFA are found to be immunomodulating in blood and tissue. However, 
little attention has been brought on the levels of these n-6 and n-3 PUFA directly in synovial 
tissues from patients with inflammatory joint diseases, and their relation to inflammation. 
Further, there is a lack of studies of the general fatty acid composition of SF from these 
patients. The general aim of this cross-sectional study was to investigate:  
• n-6 and n-3 PUFA in relation to inflammation: Do levels of  specific n-6 and n-3 
PUFA, or the n-6 to n-3 ratio in SF correlate with inflammatory disease markers, i.e 
cytokines interleukin (IL)-6 and IL-12 in SF and C-reactive protein (CRP) in serum, 
from patients with various inflammatory joint diseases?  
 
• To evaluate the inflammatory activity, and to document the fatty acid profile in SF 
from patients with inflammatory joint diseases, the following parameters were 
measured:  
o Inflammatory disease markers: The level of the cytokines IL-6 and IL-12 in 
SF, and CRP in serum from these patients, and correlations between them. 
o Fatty acid composition: The general fatty acid profile in SF from these 
patients, with specific interest in the content of n-6 and n-3 PUFA. 
 
• Additionally, since we had access not only to RA patient samples, which is most 
commonly studied, it was essential to study if there were differences between various 
groups within inflammatory joint diseases. The patients were grouped at two different 
levels; as subgroups and main groups:   
o Subgroups; Rheumatoid Arthritis (RA), PsoriaticArthritis (PsA),  Reactive 
Arthritis (ReA) and Ankylosing Spondylitis (AS),  
o Main groups: Rheumatoid Arthritis (RA) and the Spondylarhropathies (SpA) 
(which includes the three latter subgroups above)  
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THEORETICAL OVERVIEW 
The following introduction reviews the general theory about lipids and fatty acids (Section 
1.2), followed by a description of inflammation (Section 1.3) and chronic outcomes with 
emphasis on inflammatory n-6 and n-3 PUFA and cytokines (Section 1.4). The inflammatory 
joint diseases are further described (Section 1.5), before a final review of the synovial joint 
(section 1.6). 
 
1.2 LIPIDS AND FATTY ACIDS  
1.2.1 Lipids 
Lipids are a class of organic compounds which are generally soluble in organic solvents and 
insoluble in water. They provide the body with energy, but they are also important for 
isolation, mechanical support and communication in cell membranes, and as precursors for 
important signal molecules and tissue hormones. Lipids are a large and diverse group of fatty 
substances, which vary in polarity. They include the neutral lipid classes, including 
triacylglycerols (TAG), cholesterol esters, cholesterol, but also the more polar phospholipids 
(PL), and others. The lipids often consist of fatty acids. For instance, the body storage fat, 
TAG, is the main lipid found in diet, and is composed of one glycerol molecule bound to 
three fatty acids. Further, the phospholipids are composed of glycerol bound to two fatty 
acids, with a phosphate group attached, and are the major component of the cell membrane. 
The chemical composition of lipids will influence their physiological properties, which also 
relates to the composition of fatty acids incorporated in the compound (Jones & Kubow, 
2006). 
 
1.2.2 Fatty acid structure  
Fatty acids are hydrocarbon chains bound to a carboxyl functional group (–COOH) at one end 
and a methyl group (-CH3) at the other end (Figure 1.2.1). Saturated fatty acids (SFA) consist 
of hydrocarbons attached together exclusively by single bonds, whereas monounsaturated 
fatty acids (MUFA) have one double bond, and PUFA contain more than one double bond in 
the chain (Jones & Kubow, 2006).  Fatty acids are also characterized by size/chain length. 
Generally, short and medium chain fatty acids have less than eight and 16 carbons in their 
Introduction 
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backbone, respectively, and comprise of mainly SFA. Long chain fatty acids have more than 
16 fatty acids in their backbone, which generally include the bulk of the MUFA and all PUFA 
(Leonard et al., 2004; Beermann et al., 2003; Jones & Kubow, 2006). The term long chain 
PUFA (LCPUFA) commonly includes PUFA with 20 or more carbon atoms in their backbone 
(Sellmayer & Koletzko, 1999) 
 
1.2.3 Fatty acid nomenclature 
Fatty acids can be named in many ways. They are often referred to by their trivial names, but 
are more correctly identified by their systematic nomenclature according to the International 
Union of Pure and Applied Chemistry (IUPAC) rules for the nomenclature of organic 
chemistry. According to IUPAC, fatty acids are named by numbering the first, and further the 
next double bonds, counted from the carboxyl end (IUPAC, 1978). However, in nutritional 
and biological context the double bonds may be more commonly designated from the methyl 
end. It may be an easier way of numbering unsaturated fatty acids by only defining the 
location of the first double bond, since they generally are separated by methylene groups 
(CH2). The first double bond is given by the term n minus (n-), or omega minus (-). Both 
numeric systems initiate the numeric names by numbering total carbon atoms next to the 
number of double bonds. Thus, linoleic acid is referred to as 18:2n-6 (18:2-6) by n-(-) 
system (Figure 1.2.1), and all fatty acids are referred to by the n- system or by abbreviations 
throughout this thesis. 
 
 
 
      Methyl end   Two double bonds                        Carboxyl end 
                                                                                                                                                
 
          
        n ()       n-6(-6)                   
 
                                                      18:2n-6 (18:2-6)   
 
Figure 1.2.1: The structure and the n-(-) system nomenclature of linoleic acid. The first double bond is 
designated from the methyl end. Adapted and modified from the International research Livestock Institute Website 
(http://www.ilri.org/InfoServ/Webpub/Fulldocs/ILCA_Manual4/Milkchemistry.htm, 22/6-08). 
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Some common fatty acids are listed in Table 1.2.1.  SFA, such as palmitic acid (16:0), are 
written only with total carbons relative to zero, since they do not contain any double bonds. 
Typically, the MUFA have a double bond located at the n-7 or n-9 position, whereas PUFA 
containing 18 or more carbons in their backbone are restricted to having their first double 
bond only at n-3, n-6 or n-9 position (Jones & Kubow, 2006; Smith, 2001). 
 
Table 1.2.1: Fatty acid nomenclature commonly used in nutritional 
and biological context (Jones & Kubow, 2006).  
Trivial name Abbreviation Numeric name
n- system 
Palmitic acid 16:.0
Stearic acid 18:.0
Oleic acid OA 18:1n-9 
Linoleic acid LA 18:2n-6 
-Linolenic acid ALA 18:3n-3 
Dihomo -linolenic acid DGLA 20:3n-6
Arachidonic acid AA 20:4n-6
Eicosapentaenoic acid EPA 20:5n-3
Docosahexaenoic acid  DHA 22:6n-3
 
 
 
 
1.2.4 The function of n-6 and n-3 PUFA 
The n-6 and n-3 PUFA are both important components of the cell membrane, e.g. they 
influence the physical and functional properties of the membrane-bound enzymes and 
receptors, and they are important in signal transduction and activation of transcription 
factors(Calder, 2003; Haag, 2003). Further, LC PUFA have shown an increased effect on 
fluidity and functioning of the components in the membrane (Haag, 2003). Noteworthy fatty 
acids from the two families are; dihomo--linolenic acid (DGLA, 20:3n-6), arachidonic acid 
(AA, 20:4n-6), eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 
22:6n-3), which also possess different immunomodulatory activities, mainly by serving as 
precursors for bioactive lipid mediators, such as eicosanoids, lipoxins and resolvins in blood 
and tissue. Some of them are discussed later in the chapter (Calder, 2007; Calder, 2003; 
Yaqoob & Calder, 2007) 
 
1.2.5 The metabolism of n-6 and n-3 PUFA 
The PUFA linoleic acid (LA, 18:2n-6) and alpha-linolenic acid (ALA, 18:3n-3) are essential 
fatty acids, and are the precursors of the family of n-6 and n-3 PUFA, respectively. In contrast 
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to plants, the human body lack the desaturase enzymes to introduce double bonds in the n-3 
and n-6 position, and are dependent on supplement of these two essential fatty acids through 
the diet (De Lorgeril, 2007). However, the body can convert LA and ALA to the more 
important physiological active members of n-6 and n-3 families, through elongation and 
desaturation. The families are not interconvertible and may have opposing physiological 
effects (Simopoulos, 2002a). Also, the two fatty acid families are competitive, since both 
employ the same set of desaturase enzymes to form double bonds, and elongase enzymes to 
elongate the carbon chain, as well as they compete for incorporation into and realise from the 
cell membranes (Cleland et al., 2003).  Figure 1.2.2 describes the desaturation and elongation 
of n-6 and n-3 PUFA from parent essential fatty acids. 
 
        N-6 FAMILY                 enzymes                      N-3 FAMILY 
                                                      
Linoleic acid  (LA) 18:2n-6                              -Linolenic acid (ALA) 18:3n-3 
               -6 desaturase                          
-linolenic acid (GLA)  18:3n-6      Octadecatetraenoic acid 18:4n-3 
             elongase                        
Dihomo -linolenic acid (DGLA) 20:3n-6                                   Eicosatetraenoic acid 20:4n-3 
                                           -5 desaturase                                  
 *Arachidonic acid (AA) 20:4n-6                     *Eicosapentaenoic acid (EPA) 20:5n-3 
                        Elongase                             
    24:4n-6   22:4n-6                    22:5n-3 (DPA)  24:5n-3 
                                         - 4 desaturase                                    
24:5n-6                                                                                  24:6n-3 
                                                                                                 
Docosapentaenoic acid (DPA) 22:5n-6               *Docosahexaenoic acid  (DHA)  22:6n-3 
        
 
Figure 1.2.2: The elongation and desaturation pathway of n-6 and n-3 PUFA from linoleic acid and 
alpha-linolenic acid, through competition of the same set of enzymes. Fatty acids in bold text are 
either the essential fatty acids, or their fatty acid products with immunomodulatory activity. Asterisk 
show the most common products from each family. Adapted and modified from Haag et al (2003). 
Abbr: DPA; Docosapentaenoic acid. 
 
The enzymes have greater affinity for more unsaturated fatty acids like n- 3 PUFA than n-6 
PUFA, and theoretically one would expect higher contents of n-3 fatty acids in tissues. 
However, there is generally a much higher content of n-6 PUFA in tissues due to high 
availability in current Western diets (Simopoulos, 2002a; Jones & Kubow, 2006). With the 
high intake of LA, particularly AA is a major n-6 metabolite, which is a precursor for more 
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potent pro-inflammatory mediators. ALA on the other hand, is less consumed in the Western 
diet and the conversion to EPA is relatively low, and even lower to DHA. Thus, dietary intake 
of preformed  LCPUFA like EPA and DHA, which both possess anti- inflammatory effects 
and may increase membrane function, is essential (Davis & Kris-Etherton, 2003; Simopoulos, 
2002a; Simopoulos, 2002b). 
 
1.2.6 Dietary intake of n-6 and n-3 PUFA 
Dietary sources of the essential fatty acids LA and ALA are different plants that synthesise 
them. Vegetable seed oils per se, particularly sunflower, soybean, maize and safflower, and 
margarine made with sunflower or soybean oil are rich in LA. Oils from flax seed 
in particular, and also canola oil, nuts and green vegetables are the main sources of ALA.  
Further, LCPUFA may also be obtained directly from diet, which is a more efficient pathway 
for incorporation into the cell membrane, rather than metabolism from the essential fatty acids 
(De Lorgeril, 2007; James et al., 2003). Dietary EPA and DHA are found in marine fatty fish, 
but also in lean fish in less content, which is obtained from phytoplankton (algae), and may be 
consumed as marine oil (fish oil most commonly) products (Sargent, 1997). Generally, there 
is a high content of AA in traditional Western diets, and common sources are meat and 
dietary products besides what is metabolised from high intake of LA (Simopoulos, 2002a). 
 
 
1.3 INFLAMMATION 
Inflammation is the immediate reaction of the body to an environmental infectious agent or 
injury. The infectious agent is recognised by the components of the immune system, and 
series of events is initiated to eliminate the foreign substance and to repair damaged tissue. 
The major cellular components of the immune system are monocytes/macrofages, 
polymorphonuclear cells, mast cells and the lymphocytes (Harbige, 2003). 
Generally, the innate immune system recognizes the pathogen through macrophages and 
polymorphonuclear cells in the tissue. This activates the macrophages to produce various 
inflammatory mediators, including the main cytokines interleukin (IL)-1, Tumor necrosis 
Factor (TNF)- and interleukin (IL) -6, eicosanoids, platelet aggregator factors (PAF), 
enzymes degrading extracellular matrix (MMPs), and  adhesion molecules (Calder, 2003).  
These mediators trigger vasodilation, increase vascular permeability, perform chemotaxic 
effect directly or by up-regulating adhesion molecules, and further recruit monocytes and 
polymorphonuclear cells from blood to the inflammation site. The leucocytes at the site 
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eliminate the infectious components or damaged tissue commonly by phagocytosis. Further, 
there is an accumulation of other cells, proteins and plasma fluid at the site to aid in the 
signalling and elimination. Various inflammatory mediators act on each other in a complex 
manner and produce a cascade of inflammatory signals, eventually causing local oedema. If 
increased levels of macrophage-derived cytokines in plasma are obtained, a systemic 
inflammatory response will be triggered. Thus, cytokines migrate in blood and affect other 
organs, particularly stimulation of liver and brain to produce acute-phase proteins and “body 
rest” responses causing fever, anorexia and pain (Wood, 2006; Calder, 2003). The adaptive 
immune system also interacts with the innate immune system by making the infectious agents 
recognizable, after initial infection. It consists of lymphocytes, characterized by specificity of 
immunoglobulin antibodies, which recognize and coat antigens from infectious agents, 
making them recognizable for degradation by specific leucocytes. Further, they produce 
clones of the lymphocytes with the specific immunoglobulins matching the antigens. 
Lymphocytes are primary B-cells and T-cells. The main difference between the two, is that 
the T-cells are dependent upon the major histocompatibility complex (MHC) molecules from 
other cells to introduce the foreign antigen to their receptors before degradation (Harbige, 
2003). The lymphocytes enter the tissue through the lymphatic vessels and are also a producer 
of several cytokines (Wood, 2006) 
 
 
1.4 CHRONIC INFLAMMATION AND INFLAMMATORY MEDIATORS 
1.4.1 Chronic inflammation 
As a properly functioning immune system is essential for good health, malfunction of the 
system may result in long-term uncontrolled inflammation and cause chronic disease (Wood, 
2006; Mori & Beilin, 2004). Chronic diseases include the inflammatory joint (rheumatic) 
diseases, which often possess autoimmunity, meaning that the body attacks its own tissue 
(Thorsby & Lie, 2005; Marker-Hermann & Schwab, 2000) and are characterized by specific 
inflammation of synovial tissues (Walsh et al., 2005). However, all inflammatory joint 
diseases are not chronic, such as ReA which is represented by acute inflammation (Kumar & 
Clark, 2005). During chronic inflammation, there is overproduction of inflammatory 
mediators from inflammatory cells (Calder, 2003). Among others, high levels of specific 
eicosanoids and cytokines are found in synovial tissues (Hishinuma et al., 1999; Punzi et al., 
2002), but also elevated levels of the metabolic by-products reactive oxygen species (ROS) 
and nitric oxide (NO). These mediators are involved in tissue damage and inflammatory 
Introduction 
  12 
responses, including causing pain, tenderness and swelling of joints. The latter mediators may 
be modulated by n-6 and n-3 PUFA (Afonso et al., 2007; Adam, 2003). 
 
1.4.2 Pro-inflammatory cytokines (with specific emphasis on IL-6 and IL-12) 
Cytokines are small proteins from mainly leucocytes, which act in both local and systemic 
inflammation by binding to cell membrane receptors, which regulate gene expression, and 
thus alter the behaviour of the target cells (Punzi et al., 2002; Wood, 2006). These may 
possess both anti-inflammatory and pro-inflammatory effect, may act upon each other, and 
are involved in several complex intercellular relationships. TNF -  and IL-1 are the main 
triggers of a cascade of cytokines, among others IL-6, being produced. The three cytokines 
are the predominant cytokine products of the immune system cells (Punzi et al., 2002; 
Grimble & Tappia, 1998). They share common inflammatory features during joint 
inflammation, including stimulation of acute phase response, osteoclast activity, increased 
release of eicosanoids, and differentiation and proliferation of immune cells and their 
mediators in the tissue (Grimble & Tappia, 1998; Gil, 2002). IL-6 is specifically known as a 
strong inducer of hepatocytes producing acute-phase proteins, such as C-reactive protein 
(CRP) in systemic inflammatory response, but is also an important activator of local tissue 
response, including B-cell differentiation and T-cell activation and proliferation (Cronstein, 
2007). IL-12 is another important cytokine, which act later and is important in determining 
the T-helper (Th) 1 cell development in joints (Ribbens et al., 2000; Wood, 2006). It activates 
Th1 cells and other lymphocytes for production of Interferon (INF)-, which among other 
inflammatory effects is a strong macrophage activator (Paunovic et al., 2008; Punzi et al., 
2002; Wood, 2006). The four cytokines and their effect in inflammatory joints are listed in 
Table 1.4.1. 
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Table.1.4.1: Cytokines relevant in inflammatory joint disease. 
Cytokine  
(main cell source) 
 
Inflammatory property on cells  
 
Principal inflammatory effects in joint disease 
IL-1             
(M, T,F, other) 
Activation of leukocytes, endothelial cells, 
and synoviocytes 
APP;other cytokines; MMP PGE2; COX-
2; endothelial adhesion molecules; osteoclast 
activation; procoagulant 
TNF- 
(M,T,F, other) 
Activation of leukocytes, endiothelial cells, 
and synoviocytes 
 
 APP;other cytokines; MMP PGE2; COX-
2;  endothelian adhesion molecules; 
procoagulant 
IL-6*  
(M, T,F,other) 
Activation of leukocytes, endiothelial cells, 
and synoviocytes 
 
  APP (including CRP); MMP;  endothelian 
adhesion molecules osteoclast activation 
IL-12**    
(M, other) 
Activation of Th1 cell pathway and NK 
cells 
 IFN (attracting and activating macrophages;  
 other cytokines)  
Table adapted from Punzi et al. (2002) and modified from Adam (2003) *Modified from Cronstein 
(2007).**modified from Paunovic et al. (2008) and Schroder et al. (2004). Abbr: NK: natural killers, APP:Acute 
phase proteins, MMP: Matrix metalloproteinases, PGE2: Prostaglandin E2, COX-2: cyclooxygenase-2, 
M:Monocyte/Macrophage, T: T cell, F: Fibroblast 
 
 
1.4.3 n-6 and n-3 polyunsaturated fatty acids in inflammation  
 
Overall, the n-6 and n-3 PUFA may modulate the inflammation process and cytokines in two 
ways mentioned below (Harbige, 2003; Calder, 2003). 
 
1.4.3.1 N-6 and n-3 PUFA as precursors for eicosanoids 
Eicosanoids are short-lived local hormones, which play an important role in the immune 
system for rapid cellular response in damaged tissue (Adam, 2003). Specific leucocytes 
release fatty acids in membranes upon activation. Generally, AA is the precursor of the pro-
inflammatory eicosanoids, including prostaglandins (PG) and tromboxane (TX) 2- series and 
leukotriene (LT) 4-series. Among others, they are involved in release of the pro-inflammatory 
cytokines IL-1, TNF, and IL-6 (Table 1.4.1). EPA is the precursor of PG and TX 3-series and 
LT 5-series eicosanoids, which are involved in similar processes, but they generally possess 
less inflammatory potent features, including inhibiting effect upon production of cytokines. 
The fatty acids employ the same set of enzymes, cyclooxygenase (COX) and lipoxygenase 
(LOX), and they compete for release and formation at the levels of their enzymes (Calder, 
2003; Gil, 2002; Simopoulos, 2002b; Mori & Beilin, 2004). Studies performed with Dihomo-
-linolenic acid (DGLA) and its eicosanoids indicate a similar competitive and anti-
inflammatory effect upon AA by production of less inflammatory eicosanoids using the same 
set COX and LOX enzymes (Zurier, 1998). 
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1.4.3.2 Influence of n-3 PUFA on inflammatory gene expression  
Various studies have demonstrated that n-3 PUFA can influence the inflammatory pattern by  
effects on gene expression (Calder, 2003). It is indicated that n-3 PUFA are involved in 
lowering the activation of nuclear factor B (NFB) transcriptor factors. These factors induce 
expression of different pro-inflammatory products including the cytokines such as TNF-, IL-
1 and IL-6 (De Caterina & Massaro, 2005). Overall, DHA has demonstrated the most potent 
inhibitory effect (Rahman et al., 2008; De Caterina & Massaro, 2005). 
 
1.4.3.3 N-3 supplementation 
There are strong indications that use of long chain n-3 PUFA supplementation increase 
competition between EPA and AA for eicosanoid synthesis and enhance n-3 fatty acid 
incorporation into cell membranes (Sands et al., 2005; Calder, 2007; Itomura et al., 2008). 
This may further influence on the physiological properties of membranes and alter the 
inflammatory activity, including cytokines in blood and tissue (Simopoulos, 2002b; Adam, 
2003). Figure 1.4.1 summarizes the suppressive effect of n-3 PUFA on n-6 PUFA and 
cytokines during inflammation. Increased presence of cellular n-3 PUFA through diet does 
not reduce AA. They may rather inhibit AA proinflammatory products through their role as 
competitive substrates in the LOX and COX pathway, which generally produce eicosanoids 
with anti-inflammatory effect. EPA and especially DHA may also down regulate cellular 
transcription of inflammatory mediators including proinflammatory cytokines. Thus, reducing 
the n-6 to n-3 ratio in cells through consumptation of fish may reduce the AA products and 
other inflammatory mediators during inflammation (James et al., 2003; De Caterina & 
Massaro, 2005; Calder, 2003). 
 
Several clinical fish oil trials have demonstrated a beneficial effect on pain and swollen joints 
of EPA and DHA in patients with inflammatory joint diseases. Most of the studies have been 
carried out on patients with RA, whereas a few studies have been performed on the SpA 
(Henderson & Panush, 1999; Cleland et al., 2003; Goldberg & Katz, 2007). In some cases of 
the RA fish trials, reduced requirement of non-steroidal anti-inflammatory drugs (NSAIDs) 
compared to the placebo groups were reported (Goldberg & Katz, 2007), which may 
additionally lower the potential toxic drug side effects (Cleland et al., 2003). There have been 
few intervention studies regarding the influence of n-6 and n-3 PUFA on serum levels of pro-
inflammatory cytokines in RA patients, and probably no present studies of the SF n-6 and n-3 
fatty acid relation to cytokine levels in serum or SF (Sijben & Calder, 2007; Stamp et al., 
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2005). A study found significant clinical improvement and decrease of serum IL-	 after 24 
weeks of supplementation of DHA and EPA in RA patients, whereas IL-2, IL-6 and IL-8 
levels did not change (Kremer et al., 1995). Further, a study carried out by Sundrarjun et al 
(2004) found a significant increase of both serum EPA and DHA in RA patients after 24 
weeks. A significant decrease of TNF- and IL-6 was also seen in serum from these RA 
patients, but this was also seen in the placebo group. Additionally, the CRP values in the fish 
oil group were significantly decreased after 18 weeks (Sundrarjun et al., 2004). One recent 
fish oil trail on Alzheimer patients further support the relation between n-3 supplemetation 
and cytokine production by demonstrating a reduced mononuclear blood cell production of  
IL-1	 and IL-6 cytokines, in addition to elevated plasma levels of DHA and EPA, after 6 
months of n-3 supplementation (Vedin et al., 2008). 
 
 
LTB4     LOX  AA    COX  PGE2  
 
 
Figure 1.4.1: A simplified summarize of the possible anti-inflammatory effects of n -3 polyunsaturated 
fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on inflammatory cellular 
responses. Adapted from James et al (2003), and modified from Mori & Beilin (2004) and De Caterina 
& Massaero (2005). Abbr: AA; Arachidonic acid, COX (-2); Cyclooxygenase (-2), LOX; 
Lipooxygenase, PGE2; Prostaglandin E2, LTB4: Leukotriene B4 
 
 
 
1.5 INFLAMMATORY JOINT DISEASES 
There are several types of inflammatory joint diseases and there are different ways of 
classifying them. Generally, one can divide between Rheumatoid Arthritis, the 
Pro-inflammatory cytokines, COX2, 
and  several other inflammatory 
mediators 
 
Pro-inflammatory cytokines 
 Other pro-inflammatory effects
 
 Pro-inflammatory effect, 
(may also inhibit pro-
inflammatory cytokines)
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Spondylarthropaties, and Chrystal arthritis (Hansen, 2003; Haga, 2002). The pathogenic 
mechanisms of several of the diseases are poorly understood. In various cases the diseases are 
genetically linked, where specific environmental exposures may be a triggering factor of the 
abnormal function (Thorsby & Lie, 2005; Gourley & Miller, 2007). Several studies have 
suggested that the triggering factors include infectious agents, hormonal and dietary factors, 
lifestyle habits and others (Calvo-Alén & Alarcón, 2006; Gourley & Miller, 2007). 
  
1.5.1 Rheumatoid Arthritis (RA) 
RA, the disease typically associated with arthritis, is a chronic disease which mainly attacks 
the joints, but may also affect the internal organs (James et al., 2003). Symmetric polyarthritis 
(i.e. inflammation of more than five joints and on both sides of the body), which often include 
hands and feet, morning stiffness, and nodules beneath the skin, are typical characteristics of 
the disease. Features of the disease also include erosions of bone and elevated levels of the 
serum autoantibody rheumatoid factor (RF) (Arnett et al., 1988). Worldwide, approximately 
1% of the adult population has RA. The highest prevalence rate is found among women and 
elderly (Calvo-Alén & Alarcón, 2006). The general theory is that an unknown antigen is 
presented by the major histocompatability complex (MHC) to CD4 Th cells and cause 
stimulation of an immune response, eventually causing an auto-inflammatory state (Piet, 
1998). Genetic factors may account for as much as 60% of disease susceptibility, which are 
associated to MHC class II human leukocyte antigen (HLA) DR alleles (Calvo-Alén & 
Alarcón, 2006). 
 
1.5.2 Spondyloarthropaties (SpA) 
The SpA are a heterogenous group of diseases, including ankylosing spondylitis, reactive 
arthritis, psoriatic arthritis, and arthritis associated with inflammatory bowel disease (IBD).  
Characteristics within this group are inflammation of the joints and ligaments in the column, 
inflammation of the sacroiliac joints located between the basis of the spine and pelvis, as well 
as inflammation of peripheral large joints. Symptoms of the diseases can also be seen in the 
skin and mucous membranes (Khan & van der Linden, 1990). Unlike RA, SpA are frequently 
oligoarticular and asymmetrical (i.e. inflammation of two to four joints located differently on 
each side of the body), affecting both distal and proximal joints (Walsh et al., 2005). In SpA, 
there is usually no production of serum RF (Kumar & Clark, 2005), and there are higher 
levels of infiltrating polymorphonuclear leukocytes in the synovial membrane (Ritchlin, 
2007). In addition to common clinical and radiographic features of spondyloarthropathies, the 
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group also shows a similar genetic predisposal to several genes including HLA-B27 alleles, 
encoded in MHC class I. Similar to RA, the theory is that HLA –B27 antigen presentation to 
T-cells is abnormal (Breban et al., 2006; Marker-Hermann & Schwab, 2000) 
 
1.5.2.1 Psoriatic Arthritis (PsA) 
PsA causes inflammation of the joints in association with the skin disease psoriasis. Clinical 
characteristics of the disease include asymmetric oligoarthritis or RA-like symmetric 
polyarthritis, inflammation of sacroiliac joints (i.e joints connecting tail bone and pelvic 
bones), and swelling in the column or distal joints, the latter often include the upper finger 
joints. Another clinical pattern within this group is also seen including severe degradation of 
bones, often involving whole digits referred to as “telescoping fingers” (Moll & Wright, 
1973). Other charactheristics are nail lesions, inflammation of the gut and eye (Ritchlin, 
2007). The prevalence of PsA has been estimated to involve 0.3 -1% of the population, and 
concern generally elderly adults of both sexes (Gladman et al., 2005). 
 
1.5.2.2 Reactive Arthritis (ReA) 
As opposed to the other inflammatory joint diseases mentioned, ReA is an acute inflammatory 
joint disease triggered by some infectious bacteria. It is indicated that bacterial antigens is 
associated with the pathogenesis of the disease after finding their presence in synovial 
membrane of inflamed joints (Kumar & Clark, 2005). In general, the Gram Negative bacteria 
Salmonella, Yersina, Shigella and Campylobacter cause infection in the gut, whereas 
Chlamydia cause infection in the urogenital tract, but there are also other bacteria triggering 
the disease (Vahamiko et al., 2005; Haga, 2002; Kumar & Clark, 2005). ReA develops in 1-2 
% of patients after acute infection of these bacteria, and men are frequently more affected. 
Approximately 70 % of ReA patients recover from the disease in 6 months, but it is a great 
chance of relapse (Kumar & Clark, 2005). There are no established criterias for the disease. 
However, clinical characteristics are asymmetric oligoarthritis or monoarthritis, mainly 
involving the lower extremities (Vahamiko et al., 2005), and inflammation in tendon 
attachments. Inflammation of column, sacroiliac joints, eyes, and skin lesions are other 
symptoms (Kumar & Clark, 2005). 
 
1.5.2.3 Ankylosing Spondylitis (AS) 
AS, commonly named Bechterew’s disease, is the most classical subgroup of SpA, both in 
frequency and characteristics (Jacobs & Fehlings, 2008; Breban et al., 2006). It is a chronic 
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inflammatory joint disease primarily affecting the spine and sacroiliac joints, but also 
asymmetric peripheral large joints, internal organs and tendon attachments (Kumar & Clark, 
2005). The spine transform to be stiff and rigid as the disease progress, and reduced 
movement in lumbar regions, profound back pain in the daytime, and morning stiffness are 
common. The prevalence of AS is 0.1-1.4 %, and younger men are more susceptible. 
Approximately 90-95% of the AS patients are positive for HLA B-27 alleles (Jacobs & 
Fehlings, 2008). 
 
1.5.3 Social and individual impacts of the disease 
Muscoskeletal conditions, including inflammatory joint diseases, are a major burden on 
individuals, their families and the social health care system, contributing to a large part of 
chronic conditions (disability, pension etc) in welfare states. Moreover, the physical 
limitations and pain, such as inflammation and gradual destruction of joints affect social and 
economic functioning, mental health and quality of life. Economically, treatment and loss of 
labour force amounts to high costs of illness. Generally, RA is the most disabling 
inflammatory joint disease with a high mortality rate (Woolf & Pfleger, 2003; NIAMS/NIH, 
2004). Patients with PsA have lower tenderness of joints than RA patients and the disease is 
considered to be less severe (Gladman et al., 2005). In cases of AS, exercise and pain relief 
increase everyday functioning, and contribute to the fact that 80% of these patients are fully 
employed (Kumar & Clark, 2005). 
 
1.5.4 Medical treatment 
To suppress pain and reduce developmental joint destruction in patients with inflammatory 
joint diseases, medication may be included in the treatment. There are different medical 
treatments which include simple analgesics, NSAIDs, disease-modifying anti-rheumatic drugs 
(DMARDs), among others TNF- blockage, and glucocorticosteroids. TNF- blockers inhibit 
the production of TNF-, and thus block the cascade of inflammatory mediators triggered by 
the cytokine. It represents a major therapeutic advance in treatment of RA. Still, the TNF- 
blockage drugs are extremely expensive compared to DMARDs. When medical treatment is 
appropriate, the types of drugs given the patients are based on the disease characteristics. 
Overall, there are several side-effects of these drugs (Hansen, 2003; Kumar & Clark, 2005). 
Studies have documented that glucocorticosteroids and different DMARD, but also to some 
extent NSAIDs, are involved in reducing levels of cytokines, such as IL-6 (Punzi et al., 2002; 
Cronstein, 2007), and CRP (Menkes, 1993). 
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1.6 THE SYNOVIAL JOINT  
The location of which bones of the skeleton meet is called a joint (Figure 1.6.1 A). The joint 
provides normal mobility and mechanical support to the body. The synovial joints connect the 
most mobile parts of the skeleton like shoulders, wrists, fingers, hips and knees. The muscles, 
ligaments and tendons are the surrounding connective tissue, which support and stabilize the 
joint. Within the connective tissue there is a capsule, which encircles and supports the joint. 
Inside the capsule, a membrane, namely the synovium, surrounds the bones, and provides 
synovial fluid by releasing it into the joint space. The synovial fluid surrounds the articular 
cartilage surface of the bone endings (Fam et al., 2007; NIAMS/NIH, 2004). 
 
1.6.1 The synovium 
The synovium or the synovial membran merges with the joint capsule (Ropes & Bauer, 1953). 
It has no regulatory covers, which usually are present in the linings of most body cavities 
(Freemont & Denton, 1991). This provides the tissue membrane with a marked greater 
permeability than that of other tissues (Blewis et al., 2007). The synovium is composed of 
different types of cells, mainly macrophage-derived synoviocytes and fibroblast-derived 
synoviocytes, and lymphatic and blood vessels (Tak, 2006; Blewis et al., 2007). The 
membrane keeps the fluid free of debris and releases hyaluronan, which is a polysaccharide-
like molecule that keeps the SF viscous (Fam et al., 2007; Kumar & Clark, 2005). 
 
1.6.2 Synovial fluid (SF) 
SF is a hypocellular transudate of plasma that is filtered through the synovium and 
accumulates in the synovial cavity (Freemont & Denton, 1991). Normal synovial fluid has a 
pale yellowish colour, is viscous, and does normally not clot. The fluid allows easy gliding 
and normal movement of bones, and provides lubrication and nutrition to the articular 
cartilage (Kumar & Clark, 2005; Fam et al., 2007; Ropes & Bauer, 1953). 
 
1.6.3 Inflammation of the synovial tissues 
Figure 1.6.1 present a simple contrast between a normal joint and an inflammatory synovial 
joint in rheumatoid arthritis (RA). Inflammation of the synovium may increase the cell 
content from 200 cells/mm3 of normal synovial fluid to counting over 1000 cells/mm3 in SF. 
In some cases of patients with RA and ReA, high counts up to 30 000 cells/mm3 are reported 
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(Freemont & Denton, 1991). This includes inflammatory activated synoviocytes, leucocytes, 
and especially polymorphonuclear cells (Fam et al., 2007; Tak, 2006). An overproduction of 
inflammatory mediators lead to angiogenesis, swelling, and pain in joints (Adam, 2003). As a 
consequence, the permeability of the synovium and absorption through the lymphatic vessels 
are increased in inflamed joints versus normal joints. The alterations increase the amount of 
fluid entering the joint and reduce the capacity of removing colloid particles and its ability of 
keeping the fluid debris-free (Ropes & Bauer, 1953). With disease progression, the 
inflammatory mediators, particularly TNF-, IL-1-	 and IL-6 (Table 1.4.1), but also PG, are  
abundant and are known to gradually destruct the cartilage and bones, which weaken the 
surrounding muscles and ligaments, eventually leading to joint failure (James et al., 2003; 
Punzi et al., 2002; NIAMS/NIH, 2004). The activation of osteoclasts by the latter mediators 
are involved in bone destruction in established RA (Arend & Gabay, 2006), and an increase 
of their by-products ROS/NO, including peroxidation products of PUFA, cause severe 
damage of the tissue components (Kinne et al., 2006; Basu et al., 2001; Afonso et al., 2007). 
Generally, the synovial tissues are characterized by having a gross appearance. The fluid may 
clot, and are ranged from clear to turbid (Ropes & Bauer, 1953). 
 
 
A)      B) 
 
Figure 1.6.1: A) Normal synovial joint. B) Inflammation of synovial joint in Rheumatoid Arthritis 
(NIAMS/NIH, 2004) 
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1.6.4 Specific inflammatory markers 
Levels of IL-6 and IL-12 (Table 1.3.2) are both elevated in inflamed synovial tissues, and 
their levels are associated with the degree of disease activity and joint destruction. Whereas 
IL-12 is involved in the Th1 cell development, which is associated with the autoimmunity of 
the diseases, IL-6 is more frequently related to disease activity. IL-6 is considered the most 
abundant cytokine in synovial tissues, and it promotes local osteoclast activity, as well as 
influence on systemic inflammation by elevating serum CRP. Thus, the SF IL-6 is also found 
to correlate to serum CRP concentration. Both cytokines have also shown anti-inflammatory 
features. Whereas IL-6 may protect cartilage during acute disease, but promote excessive 
bone formation in chronic conditions of RA, IL-12 may rather act pro-inflammatory in early 
disease state, and anti-inflammatory in late arthritis-like disease state (Punzi et al., 2002; 
Cronstein, 2007; Matsumoto et al., 2006; Kinne et al., 2006; Ribbens et al., 2000; Paunovic et 
al., 2008; Petrovic-Rackov & Pejnovic, 2006; Petrovic-Rackov, 2005). 
 
CRP from serum accumulate in the synovial tissue, binds to phosphorylcholin, which is found 
on the surface of infectious agents and damaged tissue, and presents it to the machrophages 
that enhances phagocytosis (Wood, 2006). The protein is an inflammatory marker, which 
directly reflects the levels of cytokines and  is used to describe the pathology of the tissue 
(Dayer et al., 2007; Emery & Luqmani, 1993).Thus, it is an unspecific and sensitive indicator 
of disease activity in the majority of inflammatory diseases, including, RA, AS, ReA and PsA 
(van Leeuwen & van Rijswijk, 1994). However, IL-6 may particularly be a better marker of 
indicating histopathology than CRP (Matsumoto et al., 2006). 
 
1.6.5 Lipids and fatty acids of synovial fluid 
Most studies on lipids and fatty acids in SF of patients with inflammatory joint diseases have 
concerned patients with RA. Compared with normal SF, there was an increase of total lipids 
to 40-60 % of plasma levels, including cholesterol (15,1%), PL (38, 3%) and more highly 
neutral lipids in SF of RA patients. Cholesteryl ester (41.5 %) was the major component of 
the neutral lipids, and TAG (6.4%) was also present, in contrast to nothing found in normal 
SF. It has also been reported that the composition of lipoproteins, specifically low density 
lipoproteins (LDL) in RA patients differentiates more from blood when compared to normal 
synovial fluid (Prete et al., 1995; Bole, 1962). Further, Prete et al (1997) have suggested that 
the increased content of lipids in SF from RA patients may increase the inflammatory 
processes through the activation of the AA prostaglandin pathway. 
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The total fatty acids in SF has been estimated to be one third of the content found in serum of 
RA patients (Kim & Cohen, 1966). A more detailed study on the fatty acid composition in RA 
patients carried out by Navarro et al (2000) found approximately 40% PUFA, whereas SFA 
and MUFA  amounted to 31% and 23 %, respectively. The major components found were 
palmitic acid (16:0), oleic acid (18:1n-9), and LA (18:2n-6), contributing to 60% of the total 
fatty acid content. Also, AA (20:4n-6) was notably present. Further, it was found a low 
content of n-3 PUFA, where DHA (22:6n-3) was the major contributor. The n-6 to n-3 ratio 
can be roughly estimated to 9 and marine n-3 LCPUFA (i.e EPA and DHA) were superior to 
ALA. Because of lack of a control group with normal SF it is difficult to compare the actual 
fatty acid changes in inflamed SF. However, Navarro et al (2000) compared the SF fatty acid 
composition in RA patients by using patients with the less inflammatory disease, 
osteoarthritis (OA), as a control group. The RA patients show an increase of palmitic acid, a 
decrease of the n-3 PUFA, ALA and EPA, as well as a decrease of the elongation products of 
MUFA oleic acid, including 20:1n-9, 22:1n-9 and 24:1n-9. There was no significant change in 
composition of n-6 PUFA between the two groups. 
 
1.4.4 The origin of the lipids and fatty acids in inflamed synovial fluid 
Studies have shown that the excessive lipids and fatty acids which are present in the SF of 
inflamed joints are primary derived from blood. This is indicated from earlier studies, which 
show an altered permeability of the synovium and its vascular system during inflammation. 
However, the lipid composition and fatty acids of plasma and SF show some differences in 
RA patients. Whereas the percentage of PL in total lipids was similar, there was a higher 
fraction of cholesteryl ester and a lower fraction of TAG in inflamed SF than in serum from 
patients with RA (Bole, 1962). Further the fatty acid LA was increased and palmitic acid 
tended to be lowered in SF compared to plasma (Sugiyama & Ono, 1966). This indicates that 
other factors may also influence the lipid and fatty acid content in inflamed SF in RA patients 
(Wise et al., 1987; Prete et al., 1995; Navarro et al., 2000; Kim & Cohen, 1966; Sugiyama & 
Ono, 1966). These factors may include; altered metabolism of the synovium, local synthesis, 
selective membrane transport of specific lipoproteins into the SF (Wise et al., 1987), reduced 
capacity of removing excessive lipids, local lymphatic destruction, and release of lipids from 
degraded components of the inflamed tissue (Prete et al., 1995). Overall, the observations 
support the theory that fatty acids mainly derive from blood, as well as the composition may 
to some extent influenced by histological tissue changes. 
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II. Materials and methods 
OUTLINE 
 
SF and blood samples from 86 patients with various inflammatory joint diseases have been 
collected between June 1992 and March 1994 from the Department of Rheumatology at 
Haukeland University Hospital (HUH). During this period, patients were consecutively 
enrolled in the study ifsynovial fluid aspiration, was clinically indicated. The blood samples 
were directly forwarded for analysis of CRP at the Laboratory for clinical biochemistry at 
HUH, while the joint fluid samples were stored in freezer at -70 ˚C at the Department of 
Rheumatology. In November 2003 and March 2004, the SF samples were forwarded to the 
Research laboratory at the ear- nose- and throat-department at HUH for measurement of IL-6 
and IL-12. In august 2007 the samples were transmitted to National Institute of Nutrition and 
Seafood Research; NIFES and kept in freezer at -80 ˚C.  Table 2 shows an outline of of 
sample collection, storage and analysis. 
 
 
Table 2: Time outline of sample collection, handling and storage temperature (ºC), together with 
different analysis of aliquots of the synovial fluid (SF) samples from all patients. 
        
 Temperature (ºC) Year  Time History of SF samples 
-70 1992 0 Start of collection and storage of aliquots of SF samples 
-70 1993 1 
 
-70 1994 2 All SF samples included on freeze after ended collection  
-70 1995 3 
 
-70 1996 4 
 
-70 1997 5 
 
-70 1998 6 
 
-70 1999 7 
 
-70 2000 8 
 
-70 2001 9 
 
-70 2002 10 
 
-70 2003 11 IL-6 measurement  
-70 2004 12 IL-12 measurement 
-70 2005 13 
 
-70 2006 14 
 
-70/-80¶ 2007 15 Fatty acid analysis 
 
 ¶In freezer at -70ºC before transfer to NIFES in August 2007 and kept in freezer at -80ºC before fatty acid analysis 
 
 
 
This study took place at NIFES, in the period August 2007 to June 2008. Synovial fluid lipid 
classes of sampling tests from each of the various diseases were analyzed by laboratory 
technicians at NIFES by using a high performance thin-layer chromatography (HPTLC) 
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method. The analysis of the fatty acid composition in synovial fluid I have accomplished by 
using a gas liquid chromatography (GLC) method after being approved as an analyst at the 
Laboratory at the Laboratory for Nutrients. The statistical tool SPSS 15.0 for Windows was 
used as software to compare the data. 
 
 
2.1 ETHICS AND HUMAN SAMPLES  
 
To protect the rights of privacy and confidentiality of patients, the data material and samples 
supplied from the hospital did not include access to the personal identity. During the period of 
collecting personal information and SF the requirement of consent in writing was not yet 
inducted. Thus, patients gave their verbal consent to use the collected data for research 
purposes concerning inflammation on rheumatic diseases. Using the data for rheumatologic 
research was evaluated and approved by the Regional Committee for Medical Research Ethics 
Western Norway, REK Vest. Further, the extradition of the SF samples to a biobank for 
research purposes, kept in eppendorf vials in air atmosphere at -70˚C, was approved by the 
head of the Division of Rheumatology at the time of sample collection. 
 
 
2.2 PATIENT CHARACTHERISTICS  
All patients in the study were enrolled at the time the samples were taken under clinical 
treatment, either for routine evaluation, or after request due to increased joint symptoms. Joint 
tap was carried out due to diagnostic or therapeutic reasons, because of high disease activity 
i.e. one or more symptomatic and swollen joints. The removal of fluid may relieve pain and 
pressure on joint. Approximately half of the patients were diagnosed with Rheumatoid 
Arthritis (RA), while the remaining patients were diagnosed with different 
spondylarthropaties. This includes the diseases mentioned in the introduction: reactive 
arthritis (ReA), Ankylosing Spondylitis (AS) and psoriatic arthritis (PsA). The classification 
of RA was based on the committee of the American Rheumatism Association (ARA) revised 
diagnostic criteria (Arnett et al., 1988). PsA was classified as described by Moll and Wright 
(1973). AS was diagnosed according to the New York criteria (van der Linden et al., 1984). 
ReA is arthritis associated with urethral or gastrointestinal infection, and there are no 
validated classification criteria for the disease. Thus, classification procedures described in 
textbooks about rheumatology like Kumar and Clark (2005) are followed. 
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Table 2.2.1 presents an outline of the patient characteristics and number of patients on 
medical treatments. Nearly all of the patients were using NSAIDs on demand, but the 
frequency is not accurately registered among each of them. Approximately half of the patients 
were also using either different disease-modifying anti-rheumatic drugs; DMARDs or the 
glucocorticosteroid prednisolone. Some of the patients were on both of the latter medical 
treatments. The DMARD treatments include methotrexate, antimalaria drugs, sulphasalazine, 
gold salts including myocrisin and ridaura, and cyclosporine and pencillamine. Table 2.2.2 
specifies the different medical treatments among the patients. 
 
 
Table 2.2.1: Patient characteristics, including overall medical treatments other than NSAIDs. 
Diagnose group Patients  Gender  Age (years) 
Medical 
treatment 
    Male Female Mean Range yes no 
RA 45 15 30 57 20 - 85 36 8 
SpA 41 22 19 44 23 - 72 10 30 
PsA 19 8 11 44 23 - 63 8 11 
ReA 9 7 2 43 26 - 72 0 8 
AS 13 7 6 43 24 - 67  2 11 
Total 86 37 49 51 20 - 85 46 38 
Missing data 0 0 0 2 
Abbr; RA: Rheumatoid arthritis SpA: spondyloarthropaties, PsA: Psoriatic arthritis, ReA: Reactive 
arthritis, AS: Ankylosing Spondylitis, NSAIDs: non-steroidal anti-inflammatory drugs. 
 
 
 
Table 2.2.2: Number of patients on different medical treatments other than NSAIDs. 
MEDICAL TREATMENT Prednisolone Total data 
  Yes No  
DMARDs: Mtx 3 14 17 
 AntiMal 3 2 5 
 Slz 2 2 4 
 Other 2 4 6 
 Yes 10 22 32 
 No 13 39 52 
Total data 
  
23 61 84 
Abbr: Mtx: Metotrexate  AntiMal: Antimalaria drugs Slz: sulphasalazine. 
 
 
2.3 COLLECTION OF EXPERIMENTAL DATA 
SF and blood samples from each patient had been collected before my engagement in the 
study. To provide information about the level of inflammation, measurements of three 
inflammatory markers have been performed. We have measurements of IL-6 and IL-12 in SF 
of all patients, as well as CRP in blood from most of the patients. Table 2.3.1 presents the 
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frequency of CRP measurements and missing data in all patients and within each patient 
group. 
 
Table 2.3.1: The frequency of CRP values compared to missing data for the 
disease groups, together constituting total tests taken, in contrast to missing data.  
Diagnosis 
      
CRP Missing data Total 
RA 42 3 45 
SpA 35 6 41 
PsA 16 3 19 
ReA 8 1 9 
AS 11 2 13 
Total 77 9 86 
Abbr: SpA: Spondylarthropaties, SpA, RA: Rheumatoid Arthritis,  
PsA: Psoriatic arthritis, ReA: Reactive arthritis, AS: Ankylosing Spondylitis 
 
2.3.1 Blood tests  
Blood samples were obtained at the same time as the SF samples. Gel vials were used for 
separating serum from blood cells. The serum samples were directly forwarded for analysis at 
the Laboratory for clinical biochemistry at HUH. 
 
2.3.1.1 CRP measurement 
CRP values were determined in serum by an immunoturbidimetric method using specific anti-
human CRP serum (Orion Diagnostica) and an Axon analyzer. This measures the reduction in 
light transmission caused by particle formation. The reference area considered for healthy 
individuals were values below 10 mg/L.  
 
2.3.2 Synovial fluid  
The samples of synovial fluid were obtained from knee joints of the examined patients by the 
following method: First, the skin was disinfected by washing with chlorohexidine. To obtain 
the synovial fluid a needle was inducted into the joint space and some of the fluid was 
aspirated into the cylinder containing an anticoagulant, and later centrifuged before aliquots 
of the SF supernatant from each patient were distributed on several eppendorf tubes. Both the 
the addition of an anticoagulant and centrifugation procedure will be later discussed (Section 
4.1.3.1), as these two procedures are not well-documented. The SF aliquots had been stored 
in a freezer at -70 ˚C at the Department of Rheumatology. In November 2003 and March 
2004, aliquots of the SF samples from each patient were forwarded to the Research 
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laboratory at the ear- nose- and throat-department at HUH for measurement of the IL-6 and 
IL-12 levels, respectively.  
 
2.3.2.1 Cytokine measurements 
The levels of IL-6 and IL-12 were determined separately by Enzyme-Linked ImmunoSorbent 
Assay (ELISA). The principle of the assay is based on the principle of antibody-antibody 
interaction, where a specific monoclonal antibody able to capture the cytokine of interest is 
coated on a microtiter plate. A second monoclonal antibody, used for detection, binds a 
different area on the cytokine. When a substrate is added, a colour reaction will develop that 
is proportional to the bound content of cytokines. The concentration of cytokine (colour 
intensity) is determined by comparison with standards of known cytokine concentrations 
(Murphy et al., 2007; Favre et al., 1997).  
 
IL-6 or IL-12 capture and detection antibody pairs were compared to recombinant human (r-
hu) IL-6/ IL-12 as standards (R&D Systems Europe Ltd, Abingdon, GB). All procedures 
were performed according to the pattern of the manufacturer. 96-well microtiter plates 
(Costar Corning, NY, USA) were coated overnight at room temperature with monoclonal 
mouse anti-human IL-6 or IL-12 capture antibodies. After blocking, IL-6 and IL-12, 
respectively diluted to 1:50 and 1:5, and each of their recombinant human standards were 
added and incubated for two hours at room temperature. This was followed respectively by 
addition of biotinylated polyclonal goat anti-human IL-6 and IL-12 which allows binding of 
streptavidin-conjugated horseradish peroxidase. Then, plates were further incubated for 20 
minutes at room temperature with the latter enzyme. Tetramethyl-benzidine (TMB) (Sigma) 
and H2O2 were used as substrate. Absorbance values were measured at 450 nm using 
Softmax Pro version 4.0 on an Emax Precision microtiter plate reader (Molecular Devices, 
Sunnyvale, CA, USA). The lower detection level was settled at 9.4pg/mL for IL-6 and IL-12.  
 
2.4. FATTY ACID ANALYSIS  
The method used for analysis of the fatty acid composition in SF is named NIFES method 
354; Fatty acid determination using Gas liquid chromatography (NIFES, 2007). This modified 
method is based on the conventional accredited method NIFES method 041 (NIFES, 2002), 
that analyzes polyunsaturated fatty acids through a certain saponification and metylation 
based on Morrison and Smith (Morrison & Smith, 1964). Modification of this method is 
based on gathering metylation and extraction in the same working step introduced by Lepage 
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and Roy (1986), with some simplifications similar of what is described by Kang and Wang 
(2005) and Masood et al.(2005). The method is time saving and quantitatively less specimens 
is required, and the risk for sample loss and contamination are reduced (Kang & Wang, 2005). 
Scientific responsible for the method at NIFES is currently finalising a paper on the method 
(Araujo et al., unpublished). 
 
2.4.1 Principle 
By introducing certain samples to the strong base sodium hydroxide under boiling state and in 
presence of the strong catalyst boron trifluoride in methanol, the conversion of lipids to fatty 
acid methyl esters will occur. Methylated fatty acids are more volatile and vaporise easier on 
the column, which is a criteria for quantification by gas liquid chromatography (GLC). The 
general mechanism involves two steps shown in Figure 2.4.1. First, fatty acids of lipids are 
esterified by sodium hydroxide, creating glycerol and the salt of the fatty acids. This liberates 
the fatty acids and is called saponification.  Second, transesterification occurs when methanol 
reacts with the crude soap producing fatty acid methyl esters through methylation (Christie, 
1989; NIFES, 2007). 
 
 
Figure 2.4.1: Methylation and saponification of triacylglycerides under specific conditions. Adapted 
and modified from the Department of chemistry, Winona State University, USA 
(http://course1.winona.edu/jfranz/Lab/soaplab.htm, 16/04 2008) 
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Each fatty acid methyl ester is determined by GLC. The method is based on the 
chromatography technique which separates compounds between two phases, a mobile phase 
and a stationary phase.  A schematic of a GLC is shown in Figure 2.4.2. GLC is a technique 
used to separate volatile organic compounds. Due to each specific compounds partitioning 
behaviour between a gas mobile phase and a liquid stationary phase in a column, a separation 
is accomplished which can further be quantified. 
 
 
 
 
Figure 2.4.2:  Rough sketch of Gas Liquid Chromatography and its components. 
 Adapted from the Department of chemistry, The University of Adelaide, Australia 
(http://www.chemistry.adelaide.edu.au/external/soc-rel/content/gc.htm, 12/03-2007) 
 
 
The analyte is injected into the mobile phase where it is volatilised. Further it is passed onto 
the chromatography column. The mobile gas transports the analyte through the stationary 
phase of liquid, which is distributed as a thin layer over an inert solid matter in the column. 
The different fatty acids are passed through the gas flow at different rate set by to the 
adsorption interaction with the stationary phase. Level of interaction depends on the different 
chemical and physical properties of the various fatty acids, thus each will elute at various 
retention time. The separation relies also on other factors, among them the properties of the 
mobile phase and the temperature. The flame ionization detector (FID) is almost universally 
adopted for registering organic compounds in gas chromatography. Substances emerged from 
the column are mixed with hydrogen and air. Further they are combusted by a flame, 
generating ions that conduct electricity. A collector electrode above the flame captures the ion 
current, and measures the mass signal for each of the eluted fatty acids. The process is 
monitored by a computer programme (Christie, 1989). 
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2.4.2 Procedure 
All chemicals used in the procedure are purchased at Merck (Darmstadt, Germany) if 
otherwise is not mentioned. 
Parallels of synovial fluid homogenates (
 50 µg) were weighed in sovirel vials (10 mL) 
using an analytical balance (Mettler AT 200, Greifensee, Switzterland) linked to a computer. 
1 mL of 0,5 M NaOH dissolved in methanol and 2 mL of  BF3 (20 % in methanol) were 
added. The vials were capped and shaken 15-20 seconds on Whirlmixer (Heidolph REAX 
top, Schwabach, Germany), and further heated at 100ºC on block heater (Reacti-Therm III 
TM, Pierce, Rockford, USA) for 60 minutes. They were shaken again on the whirlmixer after 
20 minutes during the boiling state. After boiling, the tubes were cooled down, and 2 mL of n-
hexane and 2 mL water distillated from device (RiOs, Millipore SA, Molsheim, France) were 
added. The mixtures were shaken and then centrifuged with equilibrium for 4 minutes at 3000 
rpm (Centrifuge 5804, Eppendorf AG, Hamburg, Germany) for phase separation. The upper 
phase with n-hexane and methylated fatty acids was collected with Pasteur pipette, and 
transferred to smaller tubes (4 mL). The n-hexane mixture were further evaporated to dryness, 
under nitrogen (qual. 5.0), on the block heater. Then, 0,3 mL of n-Hexane was added with a 
pipette to each tube, concentrating the mixture to the specific capacity of the GLC column 
(0,20 -0,30 mg/mL). 120 µL of the n-hexane mixture (~ 0,25mg/mL) was transferred with 
pipette to tubes placed in churns inside the GLC vials (1 mL). The containing fatty acids 
methyl esters in the vials were separated and analysed by GLC. 
 
2.4.3 The GC instrument 
The GLC instrument was the model Autosystem XL from Perkin Elmer, comprising an 
autosampler (Perkin Elmer, Shelton, USA), where the GLC vials were automatically 
introduced to an on-column injector (Perkin Elmer, Shelton, USA) attached to a pre-column 
(Silica 0,53 mm ID, Imperial Eastman Tubing-22-pp-1/8, Santa Clara CA, USA). Within the 
injector, each sample is being introduced to helium gas flow that sweeps the analyte from the 
pre-column to the analytical wall coated open-tubular column (CP-sil-88, 50 m WCOT, ID: 
0.32, Middelsburg, The Netherlands), which is a narrow bore tubing of fused silica with 
polymeric material coat on the inner wall as liquid phase. During the analysis the temperature 
is increased according to a temperature program. The detector connected to the instrument is 
FID (Perkin Elmer, Shelton, USA), and the chromatography data system managing the 
instrument is Totalchrom (Perkin Elmer, Shelton, USA). Table 2.4.1 specifies the settings for 
the instrument. 
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Table 2.4.1: Information about the GLC Autosystem XL preset parameters. 
GC parameters Autosystem XL 
Carrier gas, Helium (He) 
(quality 6.0, 50L, TESS vest AS, Bergen, Norway) 
Constant flow: 1.5 ml/min  
(for samples 3, 6-9, 11-14, 18-20, 23-29, 
and 38-51) 
Constant pressure: 82 kPa  
(for the remaining samples) 
Injector On column 
Detector gas, H2  
(quality 5.0,50L, TESS vest AS, Bergen, Norway) 
450 mL/min 
Detector gas, air 
(Atlas Copco Kompressorteknikk AS, Langhus, Norway) 
45 mL/min 
Detector temperature 250 ºC 
Injector temperature Start: 50 ºC/ 0,1min  250ºC / 50min 
Time analysis 60 min 
Temperature program for the column  
Rate (ºC/min) Temp. (ºC) Isotermic 
 60 1 
25 160 25 
25 190 17 
5 220 5 
 
Abbr: GLC: Gas Liquid Chromatography 
 
2.4.4 Quantification of fatty acids 
Cod-liver oil mix prepared from cod-liver oil (Petter Møller, Lysaker, Norway), and a 
standard solution of methyl esters (Nu-Chek-Prep, Elysian, USA) in hexane (2:10) were used 
as a standard mixture of fatty acid methyl esters. The cod liver oil mix where included in the 
GLC analysis to compare the peaks detector signal from the analytical results with the known 
composition of the standard mixture. Area and percentage of each fatty acid peak were 
analyzed, and the sum of the graph area, with exception of the internal standard methyl 
nonadecanoate (19:0), was considered equal 100%. Limit of quantification (LOQ) of each 
peaks was set to 0,1 %. By addition of internal standard 19:0 (Larodan AB, Malmö, Sweden) 
in chloroform:methanol (2:1) solution (10 mg/mL), quantification of milligram fatty acids 
where determined. The internal standard was added each sovirel vials, before addition of the 
sample material, and evaporated to dryness, under nitrogen. For optimal linearity of the 
standard curve, 19:0 in chloroform/methanol was diluted and added in a concentration 
constituting 7- 30 % of the estimated total fatty acid amount of the analysis sample ready for 
GLC. The linearity of the standard curve was considered between 0,2 -0,3 mg fatty acids per 
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mL sample. In the method, limit of detection (LOD) was set to 3 mg fatty acids per kg 
sample, and LOQ was set to 10 mg fatty acids per kg sample. The limit of quantification was 
determined in the method validation when using a different GLC instrument. The GLC used 
for analyzing fatty acids in SF in the experiment has a better sensitivity than the latter GLC 
instrument, and was estimated to the double of mentioned above. Thus, the LOQ is 
theoretically 5 mg fatty acids per kg sample, which is taken under consideration in the 
interpretation of the result. 
 
Salmon liver (KM 05-06, NIFES) was added in an additional vial in the procedure used as 
control material (KM) in the analysis. The quantification of results of area % and mg/g for 
C16:0, C18:1n-9, C20:5n-3 in KM was compared to their alarm limits on the control chart, to 
ensure the accuracy of internal reproducibility. The liver was homogenized at NIFES and total 
amount fat is expected to be around 5-7 %. Because of its increased lipid content, the KM was 
added 2 mL of 0,5 M NaOH dissolved in methanol. Additionally, it was diluted with n-hexane 
(1:7) after extraction. 
 
 
2.5 LIPID CLASS ANALYSIS 
To provide an input of the lipids in synovial fluid from patients with inflammatory joint 
diseases, lipid classes from four specimens available for further examination after fatty acid 
analysis from each of the various diseases was quantified. The method used for analysis of the 
lipid classes in the synovial fluid is named NIFES method 230; Lipid class determination in 
oils, feed, tissue and tissue fluids (NIFES, 2006). The lipid classes were determined by using 
a high-performance thin-layer chromatography  (HPTLC) method applied with a densitometry 
detector described by Henderson and Tocher (1992). Known amount of lipids standards 
purchased from Sigma and Avanti were included for comparison, and scanning densitometer 
(TLC scanner 3, Camag) was used to quantify the charred lipids. 
 
 
2.6 STATISTICAL ANALYSIS 
Microsoft excel 2002 was used to calculate the mean between parallels of each fatty acid 
sample specimen. A Student’s t-test was used to compare total quantified fatty acid 
composition in percentage and mg/g, as well as calculation of percentage difference between 
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saturated, monounsaturated and polyunsaturated fatty acids (<10%) was done before 
accepting the combined parallels from fatty acid analysis. 
 
Software SPSS 15.0 for Windows was used for statistical analysis of all other data. The 
normality distribution of data was tested by using Saphiro-Wilks for n < 40 and Kolmogorov-
Smirnov test with Lilliefors correction for n 
 40. Further, Levenes test (p<0.1) was used to 
check for homogenity of variance. Most of the results are presented by median and 
interquartile range (IR) as measurements of central tendency and dispersion, since data did 
not sufficiently satisfy one of the above assumptions. 
 
• Mann–Whitney U test was used for comparison between RA and SpA groups. The test 
requires all the observations to be ranked as if they were from a single sample, and 
further the average of each sum of the ranks between the two samples are compared. 
Thus, the test is sensitive for differences in the location between the samples, i.e it is 
used to test if the median of the groups are equal. 
 
• Kruskal-Wallis H test was used to compare the four subgroups, RA, PsA, ReA and 
AS. The test is based on the principle of Mann-Whitney U test, but it handles more 
than two samples. 
o Kruskal-Wallis does not tell how the groups differed, only that they are 
different in some way. If significant differences between several groups were 
found, Mann–Whitney U test was used with the Bonferroni’s correction (P’= 
k·P) to adjust the p-value for pairwise comparison (in this case: k=4). The test 
is referred to as MWBc. 
 
• Spearman’s rank order coefficients (rho), a nonparametric test robust against outliers, 
were used for analysis of correlation. The rho was compared with published tables for 
different levels of significance (eg. 0.05, 0.01 etc). Gaussian distribution was relaxed 
and direct data values are presented in scatter plots with a straight line to provide a 
figurative association between parameters that had a significant correlation. 
 
If otherwise is not mentioned, the difference was considered significant if the p-value was 
below 0.05 (p<0.05). 
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III. Results 
 
In general, the results of various analytical parameters measured in blood or SF from all 
patients with inflammatory joint diseases will be presented as a group, as subgroups RA, PsA, 
ReA and AS (the three latter subgroups also presented as the main group, SpA). Section 3.1 
presents the levels of inflammatory markers CRP, IL-6 and IL-12, respectively in blood or in 
SF from the patients. Further, the correlation between the three inflammatory markers will be 
shown. Section 3.2 gives the results from the analysis of the fatty acid composition in SF, in 
percentage and µg/g. More specific, in part due to large data sets, a focus is set on 
significantly differences obtained during statistical analysis. Section 3.3 gives the correlation 
of n-6 and n-3 PUFA and n-6 to n-3 ratios to CRP, IL-6 and IL-12. To provide an input of the 
lipids in SF from patients with inflammatory joint diseases, lipid class composition from four 
specimens is briefly mentioned in Section 3.4. Finally, Section 3.5 gives a summary of main 
results. 
 
 
3.1 INFLAMMATORY MARKERS 
In this section, the concentration of CRP in blood (mg/L) and the cytokines IL-6 and IL-12 in 
SF (pg/mL) will be presented for all the patients as a group and as comparisons between the 
sub- and main groups. A presentation of the correlation between the inflammatory markers 
from all the patients as a group and in sub- and main groups will also be shown, first, between 
IL-6 and IL-12, secondly, between the latter two and CRP. 
 
3.1.1 Levels of inflammatory markers in patients 
Below, each of the inflammatory markers is presented as box-and-whiskers plots in three 
separate figures, where total patients and differences between the specific groups are included 
(Figure 3.1.1-3.1.3). The boxes show the median and interquartile range (IR) of each group, 
which is the 25th and 75th percentile. The whiskers present values within 1.5 box length from 
the box edge, which are not considered as outliers, whereas the marked observations outside 
of these represent outliers. Blue box plots presents the four patient subgroups; RA, PsA, ReA 
and AS, green box plots present the main diagnostic groups; RA and the SpA, and the beige 
box plots presents concentration from all the patients. Above each comparison of groups, a 
textbox with significance level is shown. 
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Figure 3.1.1 Concentration of CRP in serum from patients with various inflammatory diseases. The 
boxes show the median and interquartile range of each group. Asteriks show cases with values more than 
three times box lengths from the edge of the box, and are considered as extreme outliers. The pink 
line is the CRP reference value, 10mg /L. The area below is the concentration considered for healthy 
individuals. Blue and green textboxes above show significance level between groups, respectively 
Kruskal-Wallis test and Mann-Whitney test, p< 0.05. Different small letters (a,b) inside blue boxes 
indicate significant group differences, Mann-Whitney test with Bonferroni correction, p< 0.05. Identical 
letters indicate not significantly different, and both a and b indicate no significant group differences. 
Missing data: n=9. Abbr: RA: Rheumatoid arthritis (n=42), SpA: spondyloarthropaties (n=35), PsA: 
Psoriatic arthritis (n=16), ReA: Reactive arthritis (n=8), AS: Ankylosing Spondylitis (n=11). 
   p= 0.001 
   p= 0.055 
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• CRP: Figure 3.1.1 presents the serum levels of CRP from all the patients. The median 
was estimated to 38 mg/L (interquartile range 19-75) for all patients. This is generally 
above the reference concentration area for healthy individuals (below 10 mg/L). Of the 
total ten patients with CRP concentrations below 10 mg/L, seven of them were from 
the PsA disease group. Thus, approximately half of the PsA patient group is in the 
considered healthy reference area. 
 
CRP was significantly lower in PsA group (median 15 mg/L, IR 5-28) compared with 
the RA group (median 56 mg/L, IR 28-76)  and AS group (median 46 mg/L, IR 32-
88), p<0.000 (MWBc).  
 
The ReA group did not differ significantly from neither of the other groups (median 46 
mg/L, IR 19-110). Further, there were no statistically significant differences between 
the main groups RA and SpA (median 28 mg/L, IR 55-76), p =0.055. 
 
• IL-6: The levels of IL-6 in SF are presented in Figure 3.1.2. The median IL-6 
concentration of all the patients was 9372 pg/mL (IR 2746 - 27 916). There were no 
significant differences between neither the main groups RA (median 9754 pg/mL, IR 
4737- 26087) and SpA (median 5851 pg/mL, IR 1834 -32 321) nor the subgroups RA, 
PsA (median 5044 pg/mL, IR 1012 -16 228), ReA (median 16 166 pg/mL, 3306-
50 003) and AS (median 4396 pg/mL, IR 1834-32 321). 
 
• IL-12: The levels of SF IL-12 show seven cases with extreme outliers (Figure 3.1.3). 
The highest extreme value was 21 597 pg/mL, which is approximately hundred times 
greater than the median from all the patients. As well, this high extreme value is four 
or eight times above the three other high extreme outliers, respectively 4568 pg/mL, 
2664 pg/mL and 2572 pg/mL. Even though the rank methods used are little affected 
by extreme outliers, the highest extreme outlier was chosen to be excluded from the 
statistical analysis, and from the boxplot to provide a figurative outline. Thus, after 
exclusion, the median IL-12 in SF of all patients was 215pg/mL (IR103-369). 
 
As with CRP levels in blood, there was a significantly higher level of IL-12 in SF of 
the RA group (median 296 pg/mL, IR 176-416) compared with PsA group (median 
105 pg/mL,  IR 85-240), p=0.036, MWBc. The IL-12 level of RA group was also 
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significantly higher compared with SpA group (median 149, IR 86-254), p=0.003, 
MWBc. In between RA and PsA, the levels of IL-12 in AS (median 215 pg/mL, IR 
106-324) tended to be higher than that of patients with ReA (median 142 pg/mL, IR 
53-206), p=0.080, MWBc. 
 
Figure 3.1.2 Concentration of IL-6 in synovial fluid of patients with various inflammatory diseases. 
The boxes show the median and interquartile range of each group. Circles show outlier cases with values 1.5 
- 3 times the box lengths from the edge of the box. Asteriks shows cases with values more than three 
times the box lengths from the edge of the box, and are considered as extreme outliers. Blue and 
green textboxes above show significance level between groups, Kruskal-Wallis test and Mann-
Whitney test respectively, p< 0.05. Abbr: RA: Rheumatoid arthritis (n=45), SpA: spondyloarthropaties 
(n=41), PsA: Psoriatic arthritis (n=19), ReA: Reactive arthritis (n=9), AS: Ankylosing Spondylitis 
(n=13). 
   p= 0.193    p= 0.322 
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Figure 3.1.3 Concentration of IL-12 in synovial fluid of patients with various inflammatory diseases. 
The boxes show the median and interquartile range of each group. Circles show outlier cases with values 
1.5 - 3 times the box lengths from the edge of the box. Asteriks show cases with values more than 
three times the box lengths from the edge of the box, and are considered as extreme outliers. One 
extreme value was excluded from the plot; 21 597 pg/mL (AS patient). The significance between the 
groups was approximately the same when statistical analysis included this high extreme value. Blue 
and green textboxes above show significance level between groups, Kruskal-Wallis test and Mann-
Whitney test respectively, p< 0.05. Different small letters (a,b) inside blue boxes indicate significant 
group differences, Mann Whitney U test with Bonferroni correction, p< 0.05. Identical letters or no 
letters inside blue boxes indicate no statistically significant differences. Abbr: RA: Rheumatoid arthritis 
(n=43), SpA: spondylarthropaties (n=39), PsA: Psoriatic arthritis (n=18), ReA: Reactive arthritis (n=9), 
AS: Ankylosing Spondylitis (n=12) 
 
   p= 0.014    p= 0.003 
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3.1.2 Correlation between inflammatory markers 
Correlations between pg/mL IL-12 and IL-6 in SF, and between mg/L CRP in serum and the 
two cytokines are presented in Table 3.1. Scatter plots with a straight regression line are 
presented below to visualize the statistically significant correlations between the parameters 
(Figure 3.1.4). It is important to have in mind that Spearman’s test use the rank order 
association and does not look at the levels directly as shown in Figure 3.1.4 A and B, as well 
as the correlation do not have to be linear. To better fit the robustness test to extreme outliers 
in Spearman’s test, the four most extreme IL-12 outliers were not visualised in the figures. 
Thus, only 82 cases are shown when correlating the parameter IL-12, even though statistics 
included 85 samples, excluding only the highest extreme value. 
 
Table 3.1: An outline of statistically significant correlations between the inflammatory markers 
Spearman's rank-order correlation coeffisient rho ( p-value)  
             
Correlation RA PsA ReA AS SpA All patients  
             
IL-12 and IL-6  -0.42 (0.005**) -0.04 (0.886) -0.30 (0.433) 0.11 (0.729) 0.01 (0.927) -0.13 (0.228) 
      
 
 
 
 
 
 
 
CRP¶ and IL-12 -0.20 (0.193) 0.20 (0.465) 0.38 (0.352) 0.24 (0.498) 0.22 (0.219) 0.03 (0.778) 
      
 
 
 
 
 
  
CRP¶ and IL- 6  0.21 (0.175) 0.40 (0.126) 0.52 (0.183) 0.38 (0.283) 0.36 (0.033*) 0.34 (0.002**) 
 
Boldface numbers show significant correlations: * P<0.05 (two-tailed); **P<0.01 (two tailed). One extreme value 
was xcluded from the plot; 21 597 pg/mL (AS patient). ¶ CRP; 9 missing values; n=77 (RA; n=42, SpA; n = 35, 
PsA; n =16, ReA n=8, Bech; n=11). Abbr: RA: Rheumatoid arthritis (n=45), SpA: spondylarthropaties (n=41), PsA: 
Psoriatic arthritis (n=19), ReA: Reactive arthritis (n=9), AS: Ankylosing Spondylitis (n=13). 
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Figure 3.1.4:  Significant correlations between inflammatory markers. Straight lines represents the 
groups with significant correlations, which may include SpA (pink line), RA (blue line) or all patients 
(the black line, refered to as fit line for total). The depicted symbols represent SpA (pink triangles) and 
RA (blue dots) together constituting all patients. Text boxes give the the Spearman’s rank correlation 
coefficient (rho), with p-value in parenthesis.  (A) The statistically negative correlation between IL-12 
and IL-6 in RA group. Four high extreme values are not visualized in the plot; 21 597 pg/mL (AS) 4568 
pg/mL (RA), 2664 pg/mL (PsA) and 2572 pg/mL (RA). RA n=43, SpA: n=39, PsA: n=18, ReA: n=9, 
AS: n=11.  (B) The statistically positive correlation between C-reactive protein (CRP) in serum and IL-
6 in synovial fluid in the SpA group and total patients. CRP; 9 missing values; n=77. Abbr: Rheumatoid 
Arthritis; RA (n=42), Spondylarthropaties; SpA (n=35), Psoriasis Arthritis; PsA (n=16), Reactive 
Arthritis; ReA (n=8), Ankylosing Spondylitis;AS (n=11) 
B 
Rho:  -0.42 (p=0.005) 
Rho: 0.34 (p=0.002) 
Rho: 0.36 (p=0.033) 
A 
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• Pattern: There were no significant correlations between the inflammatory markers 
within the three subgroups PsA, ReA and AS (Table 3.1). 
 
• IL-12 and IL-6 in SF:  There was a significant but moderate negative correlation 
between the markers in the RA group (-0.42), meaning that higher levels of IL-12 may 
represent lower levels of IL-6 (Figure 3.1.4 A).  The correlation coefficients had a 
tendency to be weakly negative in all patients as a group, as well as in PsA and ReA 
subgroups (Table 3.1) (not statistically significant). 
 
• Serum CRP and SF IL-12: There were no significant correlations between levels of 
CRP in serum and IL-12 in SF.  Notably, all associations between the two, except of 
the RA group, were positive (Table 3.1). 
 
• Serum CRP and SF IL-6: There were two significant positive correlations of low 
magnitude in both the SpA group, and all the patients as a group (Figure 3.1.4 B) 
meaning that higher levels of CRP are associated with higher levels of IL-6 in these 
patient groups. In general, all correlation coefficients within both the groups and total 
patients as a group tended to have positive correlation coefficients. 
 
3.2 FATTY ACID COMPOSITION OF THE SYNOVIAL FLUID 
Only results from combined parallels that had no significantly differences in total quantified 
fatty acid composition (% and µg/g) as well as combined parallels that had percent difference 
between SFA, MUFA and PUFA below 10%, were accepted. If differing from these rules, 
those results will be discussed specifically. 
 
Throughout this section, the fatty acid composition in SF from patients with various 
inflammatory diseases will be presented. The fatty acid composition in all patients as a group 
and in various patient groups will be presented in the same manner as the inflammatory 
markers in Section 3.1.1, but in five different tables (Table 3.2.1- 3.2.3 and 3.2.5- 3.2.6). Both 
percentage and µg/g values are included. This is to provide an overall picture of the fatty 
acids. Additionally, the statistically significant differences between the groups, which all 
concern the n-6 and n-3 fatty acids, will be studied in detail in two additional tables (Table 
3.2.4 and 3.2.7). 
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Data included in various tables:  In general, tables in this section show the fatty acid 
composition by median and interquartile range (IR). Table 3.2.1 includes all data on 
percentage fatty acids, which had an average and median above 0.2 % of total 100% fatty 
acids. The same specific fatty acids are presented in µg/g, but values below LOD and limit of 
quantification LOQ were subsequently marked. The exception was 24:1n-9, 18:3n-3 and 
20:5n-3 in g/g, which were above the theoretical LOQ for the GC instrument explained in 
Material and method Section 2.4.6. The same specific fatty acids will also be presented in the 
group comparison tables, except for 24:1n-9 µg/g, which is of no specific interest. 
 
3.2.1 Total patients  
The fatty acid composition in SF shows the same tendency between percentage and absolute 
values (µg/g) from all patients with inflammatory joint diseases (Table 3.2.1). The sum total 
fatty acids in absolute values have a median of 1153 µg/g (IR 871-1421), which in percentage 
is added up to 100%. Because of this low amount of total fatty acids, and the LOQ is set to 10 
µg/g , it would be expected that percentage fatty acid composition quantified in the lower area 
of 0.9 %, will be below LOQ  for the specific fatty acid composition quantified in µg/g. 
 
PUFA>SFA and MUFA: Approximately half of the fatty acids found in the SF are PUFA 
(median 546µg/g, IR 424-700). The remaining fatty acids are quantified as SFA (median 
287µg/g, IR 226-356) and MUFA (median 271µg/g, IR 193-343) in nearly equal ratio. 
 
Linoleic acid >> oleic acid> palmitic acid: Of the single fatty acids; the n-6 PUFA, LA 
(18:2n-6), was the major contributor of fatty acids present in SF and constitutes 
approximately a median 31.9 % (IR, 28.4-34.8), which amount to in µg/g a median at 360 
µg/g (IR 269-471) of total fatty acids. The MUFA oleic acid (18:1n-9), and the SFA palmitic 
acid (16:0), were two other large contributors to the fatty acids in SF from total patients, with 
respectively a median at 220 µg/g (IR 152-285) and 179 µg/g  (IR 77-116) . Together, these 
three fatty acids constituted approximately 66% of total fatty acids. 
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Table 3.2.1: Fatty acid composition in synovial fluid from all patients 
Fatty acid 
 SFA 25.4 (23.9-26.7) 287 (226-356)
14:0           0.16 (0.06-0.24) <LOD
16:0           15.3 (13.4-16.6) 179 (77-116)
17:0           0.30 (0.26-0.34) <LOQ
18:0           8.2 (7.5-9.1) 95 (77-116)
20:0           0.26 (0.21-0.33) <LOQ
22:0           0.56 (0.40-0.73) <LOQ
24:0           0.34 (0.26-0.53) <LOQ
 MUFA 23.2 (21.1-25.5) 271 (193-343)
16:1n-7         1.0 (0.8-1.4) 12 (7-19)
16:1n-9        0.28 (0.21-0.38) <LOQ
18:1n-9         18.7 (16.7-20.8) 220 (152-285)
18:1n-7         1.6 (1.4-1.7) 18 (13-22)
20:1n-9         0.25 (0.19-0.37) <LOQ
22:1n-9         0.25 (0.06-0.54) <LOQ
24:1n-9           0.62 (0.41-0.93) 7¶ (5-8)
 PUFA 48.4 (45.6-51.8) 546 (424-700)
18:2n-6 31.9 (28.4-34.8) 360 (269-471)
20:2n-6 0.27 (0.25-0.35) <LOQ
20:3n-6         1.7 (1.4-2.0) 20 (14-27)
20:4n-6         7.0 (6.0-7.9) 76 (60-104)
18:3n-3 0.53 (0.43-0.62) 6¶ (4-8)
20:5n-3           1.7 (1.0-2.6) 17 (11-27)
22:5n-3           0.76 (0.61-0.95) 8¶ (6-11)
22:6n-3           3.9 (3.0-4.8) 41 (30-55)
0
 n-6 41.0 (37.4-44.2) 459 (344-608)
 n-3 7.0 (5.3-9.0) 74 (56-102)
 vegetable n-3 0.53 (0.43-0.62) 6 (4-8)
 marine n-3 6.6 (4.5-8.2) 67 (52-93)
n-6/n-3 5.8 (4.2-7.7) 6.0 (4.3-8.2)
AA/EPA 4.1 (2.6-6.7) 4.1 (2.6-6.7)
n-6/vegetable n-3 76.6 (66.6-101.1) 66.8 (52-85)
n-6/marine n-3 6.5 (4.6-8.9) 6.5 (4.6-9.1)
  various 3.0 (2.3-3.6) 32 (21-41)
   identified 97.0 (96.4-97.7) 1118 (839-1395)
   total 100 1153 (871-1421)
SYNOVIAL FLUID  (n=86)
All patients (µg/g) All patients (%)
 
¶Value above the theoretical LOQ for the GC instrument used in this experiment (5 µg/g)  
LOD; Limit of detection (3 µg/g). LOQ; Limit of quantification (10 µg/g). Vegetable n-3: 16:4n-3, 18:3n-3 and 
18:4n-3. Marine n-3; 20:5n-3, 22:5n-3 and 22:6n-3. Various: unidentified fatty acids. Abbr: SFA; Saturated Fatty 
acids; MUFA; Monosaturated fatty acids, PUFA; Polysaturated fatty acids. AA; Arachidonic acid (20:4n-6), EPA: 
Eicosapentaenoic acid (20:5n-3). Values are given as median and interquartile range. 
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n-6 >> n-3 PUFA: Most of the PUFA come from n-6 PUFA (459µg/g, IR 344-608), with a 
ratio of n-6/n-3 at approximately 6. Second to LA(18:2n-6), AA (20:4n-6) is the other n-6 
PUFA noticeably present, but in clearly lower amount (median 76 µg/g, IR 60-104). Of the 
low content of n-3 PUFA present (median 74µg/g, IR 56-102), marine PUFA (i.e sum of 
EPA, DPA and DHA), and especially DHA, (22:6n-3, median 41µg/g, IR 30-55), were the 
major contributors found. The PUFA ALA (18:3n-3) was present in extremely low amount 
(median 6µg/g, IR 4-8) and was the only n-3 PUFA of vegetable origin quantified above 
theoretical limit of quantification. 
 
3.2.2 A comparison between the four different subgroups 
Table 3.2.2 and 3.2.3 show the fatty acid composition in synovial fluid in the disease 
subgroups, RA, PsA, ReA and AS respectively, in percentage and µg/g. RA and AS were the 
only groups that had significantly different fatty acid composition. 
 
3.2.2.1 Patients with Ankylosing Spondylitis and Rheumatoid Arthritis 
Differences between the AS and RA-group were just seen among the amount of n-3 PUFA. 
The differences between the two groups and the specific significance level are summarized in 
Table 3.2.4. 
• Percentage and µg/g: All significant differences between the groups in µg/g included 
also differences in percentage. As seen in Table 3.2.2 and 3.2.3, it only involved the 
ratios including ratio of n-6 to n-3, n-6 to marine n-3, and n-6 to vegetable n-3 PUFA 
(percentage and µg/g) are all significantly lower in synovial fluid of patients with RA 
compared to the patients with AS disease. 
• Percentage: Additionally, in percentage there was a significantly higher level of DHA 
(22:6n-3) in the RA group (median 4.2%, IR 3.4-5.5) compared to AS group (median 
3.4%, IR 2.4-3.9). There were no other significant differences between singular fatty 
acids. Nevertheless, there were significantly higher levels of both total percentage n-3 
PUFA and total percentage marine n-3 PUFA in the RA group (respectively, median 
7.8%, IR 5.9 -10.3 and median 7.0%, IR 5.5-9.5) compared to AS (respectively, 
median 5.0%, IR 4.2-7.3 and median 5.0%, IR 3.7-6.7). The latter nearly amounts to 
all of the n-3 PUFA, and high amount in the RA group contributing to lower n-6 to n-3 
ratios of the RA group. 
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Table 3.2.4: A simplified table of the statistically significant differences in fatty acid composition 
between patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) 
Fatty acid RA AS p-value RA AS p-value
DHA (22:6 n-3)   0.012
 n-3   0.016
 marine n-3   0.040
n-6/n-3   0.003   0.004
n-6/ vegetable n-3   0.021   0.006
n-6/marine FA   0.009   0.011
% µg/g
 
Arrows pointing upwards or downwards indicate statistically significant differences,  
respectively higher or lower than the other group. Significance level (p< 0.05),  
Mann-Whitney U test with Bonferroni’s correction. 
 
 
3.2.3 A comparison between Rheumatoid Arthritis and Spondyloarthropathies  
Comparison of the SF fatty acid composition between the RA patients and the different SpA 
as one group is presented in Table 3.2.5 and 3.2.6, in percentage and µg/g. There were 
somewhat similar significant differences between RA and SpA as seen between RA and the 
specific subgroup AS. The significant differences between the RA and SpA groups are 
summarized in Table 3.2.7. 
• Percentage and µg/g: All significantly differences between the groups in µg/g, also 
included differences in percentage. Both SpA and the subgroup AS had higher SF 
ratios of n-6 to n-3 and the n-6 to marine n-33, and n-6 to vegetable n-3 PUFA than 
the RA group. Further, the SpA group had a significantly elevated ratio of n-6 to 
vegetable n-3 as compared with the RA group. 
• Percentage: Similar to the differences between RA and AS, the percentage level of 
DHA, the total n-3 PUFA and the total marine n-3 PUFA were also found to be 
significantly higher in the RA group compared with the SpA. Additionally, there was 
a significantly elevated percentage level of the singular n-3 PUFA EPA and DPA in 
the synovial fluid of the RA group, which may contribute to a significantly decreased 
ratio of AA to EPA compared to the SpA group. LA (18:2n-6) was also significantly 
different between the two groups, but the levels were decreased in RA group 
compared with SpA. A trend of decrease of AA to EPA and LA in the RA group, both 
in µg/g was also noted. 
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Table 3.2.5: Fatty acid composition (%) in synovial fluid of patients with Rheumatoid arthritis (RA) 
and Spondyloarthropathies (SpA). 
Fatty acid (%) p-value
 SFA 25.5 (24.0-27.1) 25.4 (23.9-26.1) 0.240
14:0           0.14 (0.06-0.30) 0.16 (0.08-0.21) 0.990
16:0           15.1 (13.2-16.7) 15.4 (13.8-16.5) 0.688
17:0           0.31 (0.26-0.37) 0.30 (0.26-0.32) 0.081
18:0           8.4 (7.7-9.4) 8.0 (7.3-8.9) 0.069
20:0           0.26 (0.21-0.32) 0.26 (0.21-0.34) 0.739
22:0           0.55 (0.42-0.69) 0.56 (0.40-0.85) 0.439
24:0           0.31 (0.19-0.54) 0.35 (0.30-0.54) 0.274
 MUFA 23.2 (20.3-25.4) 23.2 (21.9-26.2) 0.236
16:1n-7         1.0 (0.8-1.5) 1.0 (0.8-1.4) 0.799
16:1n-9        0.28 (0.20-0.37) 0.27 (0.21-0.38) 0.990
18:1n-9         18.4 (16.4-20.1) 19.1 (17.4-21.2) 0.152
18:1n-7         1.6 (1.4-1.7) 1.5 (1.3-1.7) 0.514
20:1n-9         0.22 (0.18-0.43) 0.25 (0.21-0.36) 0.548
22:1n-9         0.24 (0.00-0.53) 0.26 (0.10-0.55) 0.572
24:1n-9           0.61 (0.42-0.98) 0.63 (0.40-0.88) 0.733
 PUFA 48.1 (44.7-52.2) 49.1 (45.8-51.4) 0.993
18:2n-6 30.7 (27.0-34.5) 33.4 (30.4-35.3) 0.017*
20:2n-6 0.27 (0.25-0.35) 0.27 (0.24-0.34) 0.990
20:3n-6         1.7 (1.5-2.0) 1.7 (1.42-1.93) 0.928
20:4n-6         7.3 (5.9-8.2) 6.8 (6.0-7.6) 0.212
18:3n-3 0.55 (0.45-0.63) 0.52 (0.37-0.59) 0.282
20:5n-3           2.0 (1.2-3.0) 1.6 (0.9-2.3) 0.020*
22:5n-3           0.89 (0.63-1.02) 0.68 (0.56-0.89) 0.019*
22:6n-3           4.2 (3.36-5.50) 3.8 (2.59-4.32) 0.009*
 n-6 40.7 (35.3-44.1) 41.6 (39.5-44.4) 0.151
 n-3 7.8 (5.9-10.3) 6.8 (4.8-8.0) 0.008*
 vegetable n-3 0.55 (0.45-0.63) 0.52 (0.38-0.60) 0.282
 marine n-3 7.0 (5.48-9.50) 6.2 (4.3-7.5) 0.014*
n-6/n-3 4.9 (3.6-6.9) 6.5 (5.1-8.6) 0.002*
AA/EPA 3.8 (2.1-5.7) 4.9 (3.2-8.2) 0.038*
n-6/vegetable n-3 73.9 (66.4-85.8) 84.9 (68.7-108.3) 0.046*
n-6/marine n-3 5.6 (3.9-7.6) 7.4 (5.5-10.3) 0.004*
SYNOVIAL FLUID
RA, n=45 SpA, n=41 
 
Boldface numbers show significant correlations. *Significance level (p < 0.05), Mann-Whitney U test. Vegetable n-
3: 16:4n-3, 18:3n-3 and 18:4n-3. Marine n-3; 20:5n-3, 22:5n-3 and 22:6n-3.  Abbr: SFA; Saturated Fatty acids; 
MUFA; Monosaturated fatty acids, PUFA; Polysaturated fatty acids. AA; Arachidonic acid (20:4n-6), EPA: 
Eicosapentaenoic acid (20:5n-3) RA: Rheumatoid arthritis (n=45), SpA: spondyloarthropaties, including patients 
with Psoriatic arthritis, Reactive arthritis and Ankylosing Spondylitis (n=41) 
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Table 3.2.6: Fatty acid composition (µg/g) in synovial fluid of patients with Rheumatoid arthritis 
and Spondyloarthropathies 
Fatty acid (µg/g) p-value
  SFA 281 (206-357) 288 (248-365) 0.301
16:0           159 (102-227) 182 (144-227) 0.259
18:0           99 (71-118) 94 (83-117) 0.619
   MUFA 249 (178-334) 293 (215-364) 0.105
16:1n-7         12 (7-19) 12 (8-20) 0.662
18:1n-9         17 (12-21) 19 (14-23) 0.168
18:1n-7         200 (140-227) 244 (175-309) 0.080
24:1n-9           6 (5-8) 7 (5-9) 0.318
  PUFA 532 (372-674) 574 (466-755) 0.208
18:2n-6 329 (213-459) 371 (308-519) 0.058
20:3n-6         19 (13-26) 21 (13-28) 0.348
20:4n-6         73 (57-98) 77 (64-107) 0.508
18:3n-3 6 (4-8) 6 (4-9) 0.921
20:5n-3           19 (13-30) 14 (11-25) 0.779
22:5n-3           8 (6-11) 8 (6-10) 0.143
22:6n-3           45 (32-56) 40 (29-52) 0.675
  n-6 435 (289-577) 478 (401-664) 0.071
 n-3 78 (61-112) 67 (51-94) 0.508
 vegetable n-3 6 (4-8) 6 (4-9) 0.921
 marine n-3 71 (55-106) 62 (46-86) 0.205
n-6/n-3 5.1 (3.8-6.9) 6.9 (5.1-9.1) 0.002*
AA/EPA 3.9 (2.2-5.7) 4.9 (3.2-8.2) 0.060
n-6/vegetable n-3 64.4 (48.4-74.5) 76.8 (60.7-95.2) 0.033*
n-6/marine n-3 5.6 (4.1-7.6) 7.4 (5.5-10.3) 0.006*
SpA, n=41 RA , n=45
SYNOVIAL FLUID
 
Boldface numbers show significant correlations. *Significance level (p < 0.05), Mann-Whitney U test. Vegetable n-
3: 16:4n-3, 18:3n-3 and 18:4n-3. Marine n-3; 20:4n-3, 20:5n-3, 22:5n-3 and 22:6n-3.   Abbr: SFA; Saturated Fatty 
acid; MUFA; Monosaturated fatty acid, PUFA; Polysaturated fatty acid. AA; Arachidonic acid (20:4n-6), EPA: 
Eicosapentaenoic acid (20:5n-3) RA: Rheumatoid arthritis (n=45), SpA: spondyloarthropaties, including patients 
with Psoriatic arthritis, Reactive arthritis and Ankylosing Spondylitis (n=41).  
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Table 3.2.7: A simplified summarize of the significant differences in fatty acid composition between  
patients with Rheumatoid Arthritis (RA) and Spondyloarthropaties (SpA) 
Fatty acid RA SpA p-value RA SpA p-value
AA (18:2n-6)   0.017
EPA (20:5 n-3)   0.02
DPA (22:5n-3)   0.019
DHA (22:6n-3)   0.009
 n-3   0.008
 marine n-3   0.014
n-6/ n-3   0.002   0.002
AA/ EPA   0.038
n-6/ vegetable n-3   0.046   0.033
n-6/ marine FA   0.004   0.006
% µg/g
 
    Arrows pointing upwards or downwards indicate significant differences, respectively  
    higher or lower levels of the specific fatty acid compared to the other group. Significance  
     level (p < 0.05), Mann-Whitney U test. 
 
 
 
3.3 CORRELATION OF N-6 AND N-3 PUFA, AND THE RATIOS BETWEEN THEM, 
TO INFLAMMATORY MARKERS 
In this section, the cross-sectional correlations between the ratios of the n-6 and n-3 PUFA 
and the three inflammatory markers, CRP, IL-6, IL -12, will be presented. The correlation 
will be shown for all patients, the four subgroups RA, PsA, ReA and AS, and between RA 
and the three other subgroups represented as the SpA. The fatty acid parameters will involve 
all the single n-6 and n-3 PUFA, in addition to the sum of n-6 or n-3 (Table 3.3.1), and the 
ratios of total n-6 to n-3, AA to EPA and n-6 to marine FA (Table 3.3.2) in correlation to the 
inflammatory markers CRP, IL-6 and IL-12. The fatty acid correlation will only include 
absolute values (µg/g) from the quantification to avoid compensatory percent changes 
between n-6 and n-3 PUFA. 
 
• ReA: There were no significant correlations between the parameters in the ReA group 
• All significant correlations were of generally low or moderate magnitude. 
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• Single n-6 and n-3 PUFA: 
There were mainly positive significant correlations between n-6 and n-3 PUFA to IL-6 in 
SF. 
- No correlation between these PUFA and CRP of blood in SF. 
- n-6 PUFA and IL-6: All significant correlation of n-6 PUFA were positive to 
IL-6 (meaning that high levels of n-6 PUFA may also represent high levels of 
IL-6) and included mainly the n-6 AA precursors, i.e LA (18:2n-6), DGLA 
(20:3n-6), or sums of n-6 PUFA in all patients, SpA, AS or PsA. However, 
only the n-6 PUFA DGLA in SF from the RA group, correlated significantly to 
IL-6. A positive correlation was also found between AA and IL-6 in PsA. 
- n-3 PUFA and IL-6: Two fatty acid correlations were found significant to 
inflammatory parameters, and both were positive to levels of IL-6. First, a 
significant correlation between ALA and IL-6 in SF found in all patients, SpA, 
AS and the RA group. Second, a significant positive correlation between the 
marine PUFA, DHA (22:6n-3) and IL-6 in all patients. 
- n-6 PUFA and IL-12: The significant correlations between PUFA and IL-12 
were less than to IL-6, they all involved the n-6 PUFA in RA patients 
(including sum n-6 PUFA, DGLA and AA)  and AS patients (including sum of 
total n-6 PUFA and LA). The significant correlations were found weakly 
negative in the RA group and positive in the AS group. 
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Table 3.3.1: An outline of statistically significant correlations between the n-6 to n-3 ratios and the 
inflammatory markers 
 
  
            
Correlation Spearman's rank-order correlation coeffisient rho ( p-value)  
              
FA Marker RA PsA ReA AS SpA All patients  
              
  n-6 CRP¶ 0.01 (0.962) 0.23 (0.388) -0.21 (0.610) 0.44 (0.174) 0.05 (0.792) 0.01 (0.962) 
 IL-6 0.27 (0.074) 0.61 (0.005**) -0.28 (0.460) 0.61 (0.027*) 0.36 (0.020*) 0.27 (0.011*) 
 IL-12 -0.30 (0.047*) -0.02 (0.932) -0.23 (0.546) 0.63 (0.022*) 0.15 (0.365) -0.15 (0.182) 
              
18:2n-6  CRP¶ 0.02 (0.893) 0.20 (0.450) -0.12 (0.779) 0.38 (0.252) 0.09 (0.609) 0.03 0.806) 
 IL-6 0.27 (0.069) 0.54 (0.018*) -0.23 (0.546) 0.59 (0.033*) 0.35 (0.027*) 0.27 (0.012*) 
 IL-12 -0.27 (0.075) -0.04 (0.858) -0.27 (0.488) 0.66 (0.013*) 0.15 (0.357) -0.13 (0.218) 
              
20:3n-6         CRP¶ 0.01 (0.961) 0.40 (0.124) -0.45 (0.260) 0.54 (0.085) 0.15 (0.377) 0.07 (0.558) 
 IL-6 0.34 (0.024*) 0.59 (0.008**) -0.40 (0.286) 0.76 (0.002**) 0.48 (0.002**) 0.39 (0.000**) 
 IL-12 -0.30 (0.049*) 0.02 (0.943) -0.20 (0.606) 0.41 (0.162) 0.10 (0.516) -0.13 (0.242) 
              
20:4n-6         CRP¶ -0.18 (0.251) 0.00 (1.000) -0.50 (0.207) 0.53 (0.091) -0.03 (0.859) -0.09 (0.457) 
 IL-6 0.06 (0.675) 0.50 (0.029*) -0.53 (0.139) 0.51 (0.074) 0.27 (0.084) 0.15 (0.171) 
 IL-12 -0.30 (0.049*) 0.14 (0.571) -0.25 (0.516) 0.30 (0.325) 0.09 (0.592) -0.13 (0.251) 
              
 n-3 CRP¶ -0.18 (0.249) -0.10 (0.706) -0.55 (0.160) 0.00 (0.989) -0.21 (0.219) -0.16 (0.167) 
 IL-6 0.10 (0.513) 0.28 (0.250) -0.12 (0.765) 0.22 (0.471) 0.22 (0.174) 0.18 (0.093) 
 IL-12 -0.17 (0.278) 0.04 (0.881) -0.55 (0.125) 0.44 (0.133) -0.05 (0.766) -0.07 (0.507) 
              
18:3n-3 CRP¶ 0.18 (0.258) 0.00 (0.991) 0.17 (0.693) 0.19 (0.573) -0.01 (0.943) 0.09 (0.464) 
 IL-6 0.35 (0.017*) 0.37 (0.114) 0.12 (0.765) 0.69 (0.009**) 0.39 (0.012*) 0.35 (0.001**) 
 IL-12 -0.25 (0.103) -0.16 (0.518) -0.22 (0.576) 0.62 (0.025) 0.05 (0.781) -0.10 (0.376) 
              
marine CRP¶ -0.21 (0.181) -0.10 (0.706) -0.50 (0.207) -0.07 (0.831) -0.22 (0.195) -0.20 (0.090) 
 IL-6 0.08 (0.602) 0.32 (0.180) -0.05 (0.898) 0.16 (0.603) 0.21 (0.194) 0.16 (0.138) 
 IL-12 -0.16 (0.287) 0.10 (0.673) -0.57 (0.112) 0.32 (0.280) -0.04 (0.789) -0.07 (0.517) 
              
20:5n-3           CRP¶ -0.20 (0.203) -0.15 (0.575) -0.52 (0.183) -0.03 (0.936) -0.21 (0.237) -0.17 (0.134) 
 IL-6 -0.02 (0.885) 0.24 (0.312) 0.00 (1.000) -0.23 (0.448) 0.07 (0.646) 0.06 (0.574) 
 IL-12 -0.37 (0.810) 0.14 (0.571) -0.60 (0.088) 0.13 (0.681) -0.08 (0.637) -0.04 (0.744) 
              
22:5n-3           CRP¶ -0.19 (0.233) -0.22 (0.413) -0.14 (0.736) 0.30 (0.369) -0.17 (0.319) -0.15 (0.186) 
 IL-6 0.01 (0.971) 0.29 (0.235) -0.20 (0.606) 0.32 (0.280) 0.16 (0.308) 0.09 (0.434) 
 IL-12 -0.04 (0.810) -0.04 (0.858) -0.38 (0.308) -0.01 (0.972) -0.11 (0.486) -0.13 (0.227) 
              
22:6n-3           CRP¶ -0.18 (0.245) -0.10 (0.722) -0.50 (0.207) -0.08 (0.811) -0.27 (0.111) -0.20 (0.083) 
 IL-6 0.15 (0.313) 0.28 (0.249) 0.02 (0.966) 0.23 (0.459) 0.24 (0.125) 0.22 (0.039*) 
  IL-12 -0.23 (0.126) 0.05 (0.836) -0.58 (0.099) 0.38 (0.194) -0.04 (0.816) -0.09 (0.404) 
              
 
Correlations:  Boldface numbers show significant correlations. * P<0.05 (two-tailed); **P<0.01 (two tailed).  ¶ nine 
missing values; n=77 (RA; n=42, SpA; n=35, PsA; n =16, ReA; n=8, AS; n=11). Abbr: AA; Arachidonic acid 
(20:4n-6), EPA: Eicosapentaenoic acid (20:5n-3),18:3n-3; sum vegetale fatty acids, Marine; Marine n-3 fatty acids  
(20:5n-3, 22:5n-3 and 22:6n-3). RA: Rheumatoid arthritis (n=45), SpA: spondylarthropaties (n=41), PsA: Psoriatic 
arthritis (n=19), ReA: Reactive arthritis (n=9), AS: Ankylosing Spondylitis(n=13)  
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Table 3.3.2: An outline of statistically significant correlations between the n-6 to n-3 ratios and the 
inflammatory markers 
              
Correlation Spearman's rank-order correlation coeffisient rho ( p-value)  
              
FA Markers RA PsA ReA AS SpA All patients  
              
n-6/n-3  CRP¶ 0.00 (0.983) 0.42 (0.106) 0.31 (0.456) 0.40 (0.228) 0.44 (0.008**) 0.15 (0.208) 
 IL-6 0.14 (0.369) 0.24 (0.329) -0.27 (0.488) 0.46 (0.117) 0.15 (0.355) 0.08 (0.474) 
 IL-12 -0.07 (0.659) 0.32 (0.182) 0.32 (0.406) 0.26 (0.394) 0.29 (0.065) 0.00 (0.991) 
              
AA/EPA  CRP¶ 0.01 (0.948) 0.21 (0.429) 0.21 (0.610) 0.28 (0.408) 0.25 (0.154) 0.08 (0.511) 
 IL-6 0.06 (0.715) 0.11 (0.642) -0.13 (0.732) 0.60 (0.029*) 0.11 (0.491) 0.01 (0.900) 
 IL-12 -0.14 (0.358) 0.16 (0.518) 0.27 (0.488) 0.02 (0.943) 0.20 (0.215) -0.02 (0.882) 
              
n-6/vegetable  CRP¶ -0.24 (0.121) 0.29 (0.274) -0.02 (0.955) 0.21 (0.527) 0.25 (0.142) -0.03 (0.783) 
 IL-6 -0.16 (0.308) 0.27 (0.265) -0.35 (0.356) -0.51 (0.078) -0.10 (0.552) -0.13 (0.222) 
 IL-12 -0.07 (0.653) 0.41 (0.080) 0.25 (0.516) -0.62 (0.025*) 0.18 (0.258) -0.02 (0.829) 
              
n-6/marine  CRP¶ 0.11 (0.509) 0.40 (0.125) 0.29 (0.493) 0.40 (0.228) 0.39 (0.021*) 0.18 (0.119) 
 IL-6 0.18 (0.227) 0.20 (0.405) -0.23 (0.546) 0.42 (0.150) 0.13 (0.432) 0.10 (0.353) 
  IL-12 -0.15 (0.325) 0.30 (0.217) 0.38 (0.308) 0.26 (0.384) 0.30 (0.055) -0.02 (0.862) 
              
 
 
 
 
Correlations: Boldface numbers show significant correlations. * P<0.05 (two-tailed); **P<0.01 (two tailed).  ¶ nine 
missing values; n=77 (RA; n=42, SpA; n=35, PsA; n =16, ReA; n=8, AS; n=11). Abbr: AA; Arachidonic acid 
(20:4n-6), EPA: Eicosapentaenoic acid (20:5n-3), Vegetable; vegetable n-3 (18:3n-3), Marine; Marine n-3 (20:5n-
3, 22:5n-3 and 22:6n-3).  RA:Rheumatoid arthritis (n=45), SpA: spondylarthropaties (n=41), PsA:Psoriatic arthritis 
(n=19), ReA: Reactive arthritis (n=9), AS: Ankylosing Spondylitis (n=13) 
 
 
 
• Ratios of n-6 to n-3 PUFA: 
- Four correlations were found between ratios of n-6 to n-3 PUFA and 
inflammatory  parameters. The correlation only involved the SpA (including n-
6 to n-3 ratio and the n-6 to marine n-3 ratio in positive correlation to CRP) 
and AS (AA to EPA ratio in positive correlation to IL-6, and n-6 to vegetable 
n-3 PUFA (18:3n-3) in negative correlation to IL-12) 
 
 
3.4 LIPID COMPOSITION OF SYNOVIAL FLUID  
Because of the low amount of fatty acids in µg/g compared to total lipids expected to find in 
synovial fluid and a general interest of the lipid composition of the synovial fluid, an analysis 
of the lipid class composition in synovial fluid from four patients with inflammatory joint 
diseases was completed. 
• Overall, approximately three quarter of the lipids in SF from four random sample 
specimens were mainly composed of neutral lipids. Among these, there was a high 
content of cholesteryl ester, which amounts to 39 % of total lipids (Appendix I). 
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IV. Discussion 
 
This cross-sectional study of the fatty acid composition of SF from 86 patients with various 
inflammatory joint diseases was aimed to correlate specifically the n-6 and n-3 PUFA in SF to 
certain inflammatory markers in SF and serum (i.e IL-6 and IL-12 in SF, and CRP in serum), 
as well as to document the general fatty acid composition of SF in these patients. 
Additionally, the level of and correlation between the stated inflammatory markers were 
studied to evaluate inflammatory activity. The focus of the study was on all patients as a 
group, but also on significant differences between the four subgroups Rheumatoid Arthritis 
(RA), Psoriatic Arthritis (PsA), Reactive Arthritis (ReA) and Ankylosing Spondylitis (AS), as 
well as differences between the main diagnostic group spondyloarthropathies (SpA), (which 
include the latter three subgroups), and the RA group. There is a lack of studies regarding the 
fatty acid profile of SF from these patients, and probably no studies have elucidated the SF n-
6 and n-3 PUFA, in relation to local (SF) and systemic (serum) inflammatory markers. 
Certain n-6 and n-3 PUFA are found to be immunomodulating in blood and tissue, but little 
attention has been brought on their direct inflammatory correlation in SF. 
 
The discussion chapter is divided in four sections. It begins with a discussion of the materials 
(Section 4.1) and methods (Section 4.2), before the discussion of results (Section 4.3), and 
ends by a discussion of future remarks (4.4). 
 
 
4.1 DISCUSSION OF THE MATERIALS 
 
 4.1.1 Patients 
The patients were recruited 13-15 years before this study took place. In retrospect we have 
limited information about the clinical examination of these patients, besides the fact that 
patients had considerable symptoms related to the knee joint, and need of SF aspiration due to 
diagnostic or therapeutic reasons. No additional information about the disease history, 
including other illnesses and intake of supplements or lifestyle habits, such as diet, physical 
activity and smoking are registered. 
 
The patient subgroups varied in size from number of patients being 45 in the RA group, 19 in 
the PsA group, 13 in the AS group to nine patients in the ReA group. The results from the 
SpA group are thus most influenced by the PsA group, which constitutes nearly half of the 
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patients.  Ideally, the groups should have been equally distributed, but the study included all 
available material within each defined diagnose. Originally there where 46 RA SF samples, 
but one was excluded due to quantitative shortage of sample material. From patients with 
inflammatory joint diseases, there were also SF from two patients with crystal arthritis and 
one patients with inflammatory bowel disease-associated arthritis, but they were excluded due 
to their sample sizes. 
 
There was no control group included in the study, i.e SF from healthy individuals or other 
patients, to compare with the disease groups. It is not ethically acceptable to drain SF from 
healthy individuals. The procedure implies a risk for introducing bacteria into the joint and 
thus possibly inducing infection. Earlier studies carried out on both lipid composition and 
fatty acid composition in SF from rheumatic patients generally lack a control group. 
However, osteoarthritis (OA) is sometimes used in comparison with inflammatory RA (Prete 
et al., 1995; Navarro et al., 2000; Kim & Cohen, 1966). Even though both OA and 
inflammatory joint diseases share in common the feature of producing damage and even 
destruction of the joint, the principal mechanism of OA is different due to being related to 
disruption of the cartilage itself that further may cause limited signs of inflammation, and thus 
lack systemic manifestions of inflammation (Mary B. Goldring, 2007). Yet, there were not 
sufficient sample materials available from this group that only included four patients. 
 
4.1.2 The effect of medical treatment 
The RA disease group is considered as a more disabling joint disease (Haga, 2002; Woolf & 
Pfleger, 2003). Patients with high disease activity, which also may reflect elevated levels of 
inflammatory markers, are often medically treated (Hansen, 2003; Punzi et al., 2002). 
Medication, mainly DMARDs and glucocorticosteroids, but also NSAIDs, may reduce 
inflammatory markers, such as CRP and IL-6 (Punzi et al., 2002). Thus, the medically treated 
patients, primarily those on DMARDs and glucocorticosteroids, may reflect patients with 
increased levels of inflammatory markers as a starting point, and in this study include mostly 
the RA patients. Even though inflammatory markers generally reflect inflammatory/disease 
activity, the initial high levels (baseline levels before medication) of inflammatory markers 
may be reduced in medicated patients. As a consequence, the correlations between 
inflammatory markers, or between fatty acids in SF and inflammatory markers, may also be 
impaired/ disturbed in medically treated patients. The treatment bias is unavoidable in studies 
of inflammation, because of ethical reasons that one may not leave patients involved in the 
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study “untreated”. However, in the early nineties it was probably less ongoing medical 
treatments of patients than today (Table 2.2.2), which is advantageous in analysis of levels of 
inflammatory markers. 
 
Since there are different frequency of use of DMARD and glucocorticosteroids between 
groups of patients (Table 2.2.1), i.e high frequency in RA and low frequency in SpA group, 
including no frequency in the ReA group, little frequency in the AS group and below half on 
medical use in the PsA group, medication may influence the statistical results. This includes 
levels of inflammatory markers and correlations primarily of the highly medicated RA group. 
However, the impact of medical treatment, both in all patients and comparisons between 
groups, in relation to analytical values and correlations will not be further discussed 
throughout this thesis as it is beyond the scope of the work. 
 
 
4.1.3 SF samples 
  
 4.1.3.1 Anticoagulants and centrifugation 
SF from patients with inflammatory joint diseases has a tendency to clot, and transfer of 
samples to tubes containing an anticoagulant, more specifically lithium heparin, and 
centrifugation is recommended. An advantage of centrifugation before freezing may be that it 
makes the material easier to handle during analysis by avoiding clotting factors (Freemont & 
Denton, 1991). Notes from the specific project and common procedures during this time 
indicate strongly that an anticoagulant was added to our SF samples, and that there is a high 
possibility that the samples were centrifuged before stored in freeze. However, in retrospect 
there exist some uncertainties if the anticoagulant added was EDTA or heparine. 
 
Since there is a small possibility that specifically the centrifugation was not completed, the 
effect this may have upon analyses will be discussed. In several other studies, the SF samples 
are centrifuged before freezing. In order to test the effect of centrifugation, Aman et al (1999) 
compared the content of specific collagen propeptides in five samples of SF in patients with 
inflammatory joint diseases before and after centrifugation, and found a slight decrease of 
propeptides. Four of five centrifuged SF samples had between 0.2 -1.4 % less propeptide 
content than native SF samples. Further, Bole et al (1962) analysed the lipid content of both 
the cell poor supernatant and the solid cell pellet of SF after centrifugation, and found that the 
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cell pellet accounted for 10 % of the value of total lipids and lipid classes in the cell-poor 
fraction of SF. 
 
4.1.3.3 Effect of storage conditions and stability of cytokines and fatty acids 
Some aliquots of the SF samples have been stored in the freezer at -70 ºC between nine to 
twelve years before cytokine analyses, and other aliquots additionally three years at -70 ºC 
before transferred to NIFES and kept in freezer at -80 ºC in maximum five months before 
fatty acid analysis. No antioxidants have been added to the SF samples before storage. SF is a 
transudate of plasma and there is some literature regarding blood samples and stability and 
effects of both cytokines and fatty acids after freezing and storage time. 
 
Cytokines: Studies on freeze and thaw cycles and different storage temperature of both plasma 
and serum find cytokines relatively stable, including TNF-, IL-6, IL-, IFN-  and IL-	,. 
However, TNF- is the least stable of the cytokines, and in one case IL-6 is also suggested as 
a less stable cytokine (Flower et al., 2000; Thavasu et al., 1992; Aziz et al., 1999). Plasma or 
serum levels of TNF- are both lowered at room temperature in comparison to 4 ºC and -70 
ºC frozen material after 20 days (Aziz et al., 1999). On the contrary, Flower et al (2000) 
found an increase of TNF- levels after three freeze and thaw cycles with samples stored at -
70 ºC (left one hour in room temperature between cycles). Generally, to avoid breakdown of 
certain cytokines, prompt processing of serum or specific EDTA-plasma stored at -70 ºC has 
been recommended (Flower et al., 2000; Aziz et al., 1999; Thavasu et al., 1992). Kenis et al 
(2002) carried out an accelerated stability testing protocol, which included time-delay, sample 
processing, clotting temperature and freeze and thaw cycles on serum IL-6 and IL-10 from 
post-surgical patients before enzyme immunoassay, and estimated that IL-6 and IL-10 can be 
stored at -20 ºC and -70 ºC respectively and be stable for decades. 
The different studies carried out on plasma and serum indicate that storage of SF at -70 ºC 
without freeze and thaw cycles before ELISA analysis generally should not influence the 
relative IL-6 and IL-12 cytokine stability. However, the SF cytokine stability is dependent on 
type of cytokine, and may be improved if the materials have been centrifuged before freezing 
(Flower et al., 2000; Freemont & Denton, 1991). 
 
Fatty acids: Moilanen and Nikkari (1981) showed that the fatty acid composition of plasma 
measured shortly after collection and after one year storage without antioxidant at -60 ºC is 
approximately the same. The small changes that occurred were mostly believed to be minor 
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modification of the GLC methodology during the year, and few were believed to be due to 
lipid peroxidation (Moilanen & Nikkari, 1981). Further, Hodson et al (2002) found similar 
fatty acids of TAG in plasma to be stable at - 80 ºC, first analysed 1-1.5 years after collection, 
then the same samples were frozen and thawed for a repeated analysis 2-2.5 years later. Given 
these observations, it seems that fatty acids of plasma may be stable for at least four years at 
such low temperatures, even with freeze and thaw cycles. Stability studies on SF fatty acid 
profile are lacking, and even though our samples have only been exposed to two freeze thaw 
procedures, it should be emphasised that our SF samples have been stored for 12-15 years. 
Thus, we can not exclude if SF samples have been degraded or not, but other sample materials 
are often stored for decades in biobanks. 
 
Further, studies found total amount of fatty acids (mg/L) to decrease significantly in red blood 
cells (RBC) at higher temperatures (-20 ºC) after nine weeks. After 17 weeks, the percentage 
of all fatty acids were significantly changed, including a decreasion of all PUFA and a 
increasion of all SFA at baseline. Both hemolysis and lipid peroxidation may cause the 
lowered content of fatty acids. On the other hand, an addition of an antioxidant prevented the 
significantly changes of total fatty acid amount (mg/L) and fatty acid percentage after 17 
weeks at -20ºC (Magnusardottir & Skuladottir, 2006). 
 
Concerning the the inflamed SF, lipid peroxidation is found to be increased (Basu et al., 
2001). Overall these studies indicate that the fatty acid composition may be relatively stable 
in samples after storage at -70 ºC, but addition of antioxidant should be considered even for 
such low levels as -70 ºC, particularly due to increased lipid peroxidation in SF (Moilanen & 
Nikkari, 1981; Hodson et al., 2002; Magnusardottir & Skuladottir, 2006; Basu et al., 2001). 
Still, our SF samples have been stored under the same conditions and if possible changes have 
occurred it would concern all samples. 
 
 
4.2.3 Blood samples 
CRP in serum is measured instantly, and may be a more reliable marker than the long-term 
stored cytokines. However, it is an indirect measurement of the inflammation of the SF as it is 
a systemic inflammatory marker of joint inflammation/disease, which appears in the acute 
phase response. Though, from earlier studies it appears to exist a good correlation between 
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disease activity and levels of CRP in the inflammatory joint diseases, and the turbidometric 
assays are widely used in clinical practice (van Leeuwen & van Rijswijk, 1994). 
 
 
 
4.2 DISCUSSION OF THE METHODS 
  
4.2.1 ELISA 
 
Several studies have shown that different methodologies, as well as biological and pre-
analytical factors, can contribute to differences in determination of cytokines (Aziz et al., 
1999; Kenis et al., 2002). However, ELISA has since the 1980s been an exceedingly used 
method for analytical and clinical investigations of innumerable analytes in patient samples, 
which include cytokines and SF (Lequin, 2005; Kenis et al., 2002). Three to four years before 
this study was initiated, the cytokine analyses were performed according to guidelines of the 
kit manufacturer by recognised analysts at HUH. Since the notes does not inform about any 
experimental errors we assume the two specific analyses were successfully completed. 
Generally, during ex vivo ELISA processing, including sample collection and storage, the 
cytokines are exposed to degradation and induction of cytokines may also occur (Kenis et al., 
2002). A disadvantage of the indirect measurement is that cross-reactivity may occur with the 
secondary antibody, resulting in nonspecific signal. 
 
4.2.2 Fatty acid analysis of synovial fluid  
 
Due to problems during the experimental procedure, including instrumental errors and 
addition of internal standard in proper concentration to the fatty content in different samples, 
all the SF samples went through two freeze and thaw cycles before analysis. To solve the 
instrumental problems, modification on the GLC instrument was also done between analyses, 
which resulted in some samples being analysed under constant flow and some samples being 
analysed under constant pressure (Table 2.4.1) 
It has arisen some difficulties during one-step analysis when compared to two-step analysis, 
more specifically low values of 16:0, and high values of 20:5n-3 fatty acids for KM on the 
control chart. The risk for sample loss, lipid peroxidation, and contamination are reduced 
during procedure, thus increased recovery of LCPUFA resulting from higher levels of 20:5n-3 
and lower levels of 16:0 fatty acids are expected on control chart. On the other hand, the 
measurement uncertainty of NIFES one-step method is somewhat higher for KM at control 
chart than traditional method. 
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The one-step method was used for analysis since it may quantify fatty acids in limited amount 
of sample of low fatty content, such as in the case of SF samples. Synovial fluid is considered 
to have extremely low amount of lipids, which makes it even more difficult to quantify. On 
the contrary, the NIFES one-step method has also been suggested as less efficient in 
dissolving human matrices, as there were observed increased variation between parallels of 
RBC. Thus, homogenization during the boiling step is specially important for these matrices. 
One challenge was proper homogenization of SF samples before weight, as the matrice 
viscosity may differ between patient samples and may be difficult to handle. Eventhough, the 
homogenization process was highly emphasised during the procedure, the separation phase of 
SF samples was less clear in comparison to in KM samples. 
 
Parallels were used to monitor homogenization of the material and quality of the method etc. 
During the time of analysis there were not specifically set accepted differences between 
parallels. At present the same accepted differences between parallels as the traditional method 
are used for the one-step method. This is only temporarily, since also the parallels of different 
material are commonly seen to have increased difference in the one-step method.  I did not 
follow the same acceptance rules for difference between parallels, as the one-step method is 
not accredited. On the other hand, a Student’s t-test was used to compare total quantified fatty 
acid composition in percentage and mg/g, as well as calculation of percentage difference 
between saturated, monounsaturated and polyunsaturated fatty acids (<10%) was done before 
accepting the combined parallels from fatty acid analysis. I might have controlled the 
accordance between parallels more strictly according to the traditional method, which 
including percentage difference between each fatty acid of parallels from all 86 SF samples. 
However, both differences between microgram per gram and percentage for each fatty acid 
were also overviewed by myself and other analysts at the laboratory to avoid inclusion of 
parallels that differentiated within the SFA, MUFA and PUFA.  Overall, there were no 
significant differences between total quantified fatty acids in % and µg/g according to Student 
t-test. In a few cases, parallels may differ more than 10% between sum of SFA, MUFA and 
PUFA, but due to earlier analyses with similar results (first freeze and thaw cycle), the results 
were kept. 
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4.3 DISCUSSION OF RESULTS 
The discussion of results is presented in same order as the aims of the study and starts off with 
the discussion of the main aim. The results of the correlation of n-3 and n-6 PUFA to 
inflammatory markers only includes absolute values, i.e PUFA in µg/g, and thus only PUFA 
in µg/g will be discussed (Section 4.3.1).. This is to avoid the inclusion of compensatory 
changes as a percentage of one n-6 fatty acid may be higher even though the amount of this 
fatty acid do not differ from SF of another patient, given amount of another fatty acid are 
lower. Further, the discussion of the results on inflammatory markers will be presented 
(Section 4.3.2), before the final discussion of the fatty acid composition (Section 4.3.3). For 
the same reason as mentioned above (to avoid inclusion of compensatory changes) the 
discussion of the fatty acid composition results will emphasise on absolute values. However, 
percentage fatty acid composition in SF in patients, mainly in the RA group, will also be 
discussed to relate our results to existing literature. Furthermore, multiple statistical 
comparisons of the results have been completed, which is unavoidable in relation to the fatty 
acid profile.  Thus, the results should be cautiously interpreted to avoid highlighting 
significant differences that might have arisen by chance due to multiple statistical analyses. 
 
4.3.1 Correlation between n-6 and n-3 PUFA in SF and inflammatory markers 
ReA was the only patient group that did not have any correlation between their n-6 and n-3 
PUFA and inflammatory parameters. Also, ReA was the only acute inflammatory joint 
disease group included, and patients normally recover from the disease in 6 months. 
Concerning the three other patient groups, RA, PsA and AS, all are recognized as chronic 
inflammatory joint diseases involving long-term overproduction of inflammatory markers. In 
these chronic conditions there were found significant correlations of levels of several n-6 and 
n-3 PUFA, but also in cases between levels of n-6 to n-3 ratios, to inflammatory markers. The 
significant correlations of n-6 and n-3 PUFA were mostly positively associated to IL-6 in SF, 
involving all chronic disease groups, but were observed less frequently in SF from the RA 
group. 
 
The bulk of the significant correlations did not concern the immunomodulating PUFA; AA, 
EPA and DHA, and in cases involved opposite significant correlations than expected. Rather, 
the significant correlations concerned LA and DGLA positively associated to IL-6, further 
contributing to positive correlations between total sum of n-6 and IL-6 in the groups. 
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Like EPA, DGLA have been associated with anti-inflammatory effects through its eicosanoid 
products (Navarro et al., 2000; Zurier, 1998). Yet, in this cross-sectional study, DGLA was 
the only fatty acid which correlated positively to pro-inflammatory IL-6 in SF for all patient 
groups (except for ReA) meaning that high levels of DGLA are associated with high levels of 
the pro-inflammatory IL-6 suggesting otherwise for this particular fatty acid in local inflamed 
synovial tissue. However, high levels of DGLA are found in plasma of RA compared to 
plasma of healthy individuals (Navarro et al., 2000), and elevated levels have also been seen 
in colorectal mucosa tissues of diseased cancer patients compared with paired normal mucosa 
(Fernandez-Banares et al., 1996). Navarro et al (2000) and other studies have suggested that 
high levels of DGLA in RA plasma will attenuate inflammation, through their less 
inflammatory eicosanoids, and that the conversion step from DGLA to AA might be more 
more slowly in these patient. Thus, preservation of DGLA may serve as a protective 
mechanism (Zurier, 1998; Chilton et al., 2008). On the other hand Fernandez-Banares et al 
(Fernandez-Banares et al., 1996) speculated about the DGLA present in colorectal mucosa 
tissue and its participation in carcinogenesis. 
 As with high levels of LA, also high levels of DGLA might be expected in association to 
inflammatory markers, since there generally are expected a conversion of these fatty acids to 
AA (Lin & Salem, 2005; Chilton et al., 2008) However, levels of AA were commonly not 
correlated to inflammatory markers (except to IL-6 in the PsA group). From literature 
concerning blood and immune cells, high levels of AA may be linked to increased 
inflammation, and thus increased disease activity (Harbige, 2003). It has also been speculated 
that in tissues of active inflammation there might be a consumptation of AA due to increased 
synthesis of prostaglandins and thus levels might be reduced (Esteve-Comas et al., 1992; 
Arslan et al., 2007). In this way it might be difficult to determine the relation between the AA 
to IL-6 in tissues without any further data on prostaglandin levels.  
Concerning correlation og n-3 PUFA to inflammatory markers there were found positive 
correlations both between the essential PUFA ALA (18:3n-3) and IL-6 in several groups, and 
one positive correlation of DHA (22:6n-3)  to IL-6 in all patients, meaning high levels of 
these fatty acids in SF also represent higher levels of pro-inflammatory IL-6. The correlation 
of DHA to IL-6 in all patients was unexpected, but it is difficult to make any assumptions as it 
is only seen in one incidence of the lowest magnitude, and thus might be statistically 
significant by chance. However, it should not be ignored, as other expected correlations are 
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trusted. As for ALA, levels are reported to be decreased in inflamed SF of RA patients 
(Navarro et al., 2000). In contrast to our findings related to IL-6, higher levels of ALA are 
normally associated to anti-inflammatory activity in blood through conversion to EPA and 
DHA, though this pathway appears to be limited (Williams & Burdge, 2006). 
All n-6 fatty acids which were correlated to IL-12, were also found to correlate significantly 
to the cytokine, either in the RA group or the AS group, suggesting a relationship between the 
n-6 PUFA and IL-12. Unexpectedly, over half of these correlations concern a negative 
correlation to the RA group. In the RA group DGLA correlated negatively to IL-12, whereas 
it correlated positive to the more studied and accepted inflammatory marker IL-6. In Section 
3.2.1 the possible antagonistic effect between IL-12 and IL-6 will be discussed, suggesting 
IL-12 to possess late anti-inflammatory effect. Thus, high levels of n-6 PUFA and low IL-12 
levels do not necessarily represent less inflammation in the RA group. On the contrary, these 
two cytokines show similar positive properties in SF from the AS group. This two findings is 
supported by other studies which suggest IL-12 have both early pro-inflammatory and late 
anti-inflammatory effects in arthritis-like disease (Paunovic et al., 2008). Overall, even 
though n-6 PUFA is related to the IL-12, which may further influence the Th1 pattern, the 
cytokine is somewhat controversial in the inflammatory process, and little can be concluded 
on disease activity from these associations.   
There were few statistically significant correlations between n-6 to n-3 ratios and the 
inflammatory markers. Of 72 correlations, only four significant correlations were seen in 
either the AS group or the SpA main group. This might indicate statistical significance by 
chance however they were generally as expected according to theory. The correlations 
involved that increased n-6 to n-3 ratios represented either higher levels of the inflammatory 
markers CRP in serum or IL-6 in SF, or low levels of IL-12 in SF. These correlations to the 
two cytokines were probably influenced by levels of n-6 PUFA, LA or DGLA.  
The correlation between absolute values of fatty acids and inflammatory markers may be 
significantly positive in cases of IL-6, because inflammation is accompanied by excessive 
levels of lipids (Bole, 1962), and further elevated levels of fatty acids in SF. Hence, there may 
be a higher level of lipid-derived fatty acids, no matter type of fatty acids (more commonly 
seen in ALA,  DGLA and LA), which may rather represent excessive lipids not their potential 
immunomodulating effect, or the possible preservativion of n-3 PUFA and DGLA in SF to 
protect the tissue. If this should be the case, further speculations to why there are no 
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correlations between LCPUFA to inflammatory markers might be that excessive entering of 
these fatty acids are further consumed due to oxidative stress and prostaglandin synthesis in 
inflamed SF tissue, or that SF n-3 and n-6 PUFA simply does not reflect inflammatory 
activity. Correlation of percentage fatty acids to inflammation may be a better way to 
illustrate the relation between the two fatty acid families, and not the possible excessive fatty 
acids entering the synovial fluid. Then again, the result may be based on compensatory 
changes of percent values. Both these factors make it difficult to draw conclusions about the 
single fatty acids. However, the ratios of n-6 to n-3 fatty acids in micrograms per gram may 
represent better their relationship to inflammation in SF. This is because they may represent 
excessive fatty acids in both families as a response to inflammation, and avoids compensatory 
changes. Thus, if presumed that both n-3 and n-6 PUFA increases due to excessive lipids 
levels of inflamed SF, these results should be emphasised in the evaluation of inflammation in 
SF. 
 
 
4.3.2 Inflammatory markers 
4.3.2.1 Levels of inflammatory markers 
Levels of inflammatory markers did not differ significantly between RA and AS in the same 
manner as the n-6 and n-3 fatty acids. Further, our results, together with what is described in 
the literature, indicate that IL-6 might be a more relevant marker for describing inflammatory 
activity in SF for all patients and groups in comparison to CRP and IL-12. Below, the results 
will be discussed together with findings from other studies. 
 
CRP: Significantly higher levels of CRP in the RA (median 56 mg/L, IR 28-76) and AS 
groups (46 mg/L, IR 32-88) were found in comparison to PsA group (median 15 mg/L, IR5-
28). These findings are in accordance with the literature where CRP levels are described as 
high in RA and AS, respectively with mean levels of CRP of 69.2±36.4 mg/L and 50 mm/L 
previously reported in some patient populations (van Leeuwen & van Rijswijk, 1994; Kumar 
& Clark, 2005). Further, Mease et al (Mease et al., 2005) reported that CRP is not 
consistently elevated in PsA patients even with active inflammation, and thus may be a less 
reliable inflammatory marker in serum of these patients. From our CRP measurements, as 
much as seven of 16 patients with PsA, were within the reference area of healthy individuals 
(below 10mg/L). Also, studies find a generally lower disease activity of the PsA group in 
comparison to the RA group (Gladman et al., 2005) 
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IL-6: IL-6 has been suggested as a better marker of indicating histopathology than CRP, 
including infiltration of inflammatory cells in synovial tissues (Matsumoto et al., 2006). 
Additionally, studies have compared IL-6 levels in RA and PsA to less inflammatory OA. 
Significantly higher levels are found in both serum and SF in RA and SF of PsA patients 
(Hermann et al., 1989; Matsumoto et al., 2006), and it may be the most abundant cytokine in 
inflamed synovial tissues (Punzi et al., 2002). We found similarly high IL-6 levels in SF from 
the subgroups and the main groups which indicate that IL-6 indicate inflammation for all 
groups, and median levels in all patients were at 9372 pg/mL (IR, 2746-27 916). Yet, Steiner 
et al (1999) found IL-6 levels in SF from RA and ReA patients at a much lower median 
measured to 4500 pg/mL, with a range of 400-80 000 pg/mL for almost all patients. IL-6 is 
considered to be relatively stable (Kenis et al., 2002; Thavasu et al., 1992; Flower et al., 
2000). The IL-6 levels seems to be widely distributed in both patient groups, and the range of 
our patient group was more narrow (0 – 54 626pg/mL) in comparison to patients studied by 
Steiner et al (1999). Still our results support high IL-6 levels with a broad range are present in 
inflamed SF of these inflammatory joint disease patients. 
 
IL-12: Elevated levels of IL-12 have been seen in both serum and SF of RA patients 
(Petrovic-Rackov & Pejnovic, 2006; Ribbens et al., 2000; Petrovic-Rackov, 2005). In a study 
carried out by Ribbens et al.(2000), levels of IL-12 in SF had a median of 269 pg/mL 
(interquartile range IR, 143-355) in RA patients, and  516 pg/mL (IR, 197-984) in ReA 
patients. IL-12 levels in our RA patients were measured at similar levels (median 296 pg/mL, 
IR 176-416), whereas ReA patients had a tendency of lower levels. We found one statistically  
significant difference between subgroups, namely lower levels in the PsA group (median 105 
pg/mL, IR85-240), which together with ReA group contributed to significantly lower levels of 
IL-12 in the SpA group (median 149 pg/mL, IR 86-254), in comparison to the RA group. Yet, 
not much is known about the influence of high IL-12 levels and disease activity in SF of SpA, 
whereas SF IL-12 from RA patients has both shown good and poor correlation with disease 
activity. Further it may possess both proinflammatory and anti-inflammatory effects. 
(Petrovic-Rackov & Pejnovic, 2006; Petrovic-Rackov, 2005; Ribbens et al., 2000). As a result 
it is difficult to make any associations about disease activity in these patients. 
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4.3.2.2 Correlation of inflammatory markers 
There was found no correlation between the inflammatory markers within the subgroups of 
SpA. 
 
SF IL-12 and IL-6: IL-12 and IL-6 are both produced by macrophages and reflect different 
pathological tissue events, IL-12 being of higher influence on the Th1-cell pattern and IL-6 
being in direct relationship between systemic and local inflammation (Cronstein, 2007; 
Paunovic et al., 2008). Even though high levels in SF of all patients, the levels do not 
necessarily reflect severity of the disease. In our result, there was observed a negative 
correlation between IL-12 and IL-6 in the RA group. There are high levels of both of these 
cytokines and they are generally recognised to possess pro-inflammatory effects. Still they 
have shown anti-inflammatory features. Whereas IL-6 may protect cartilage during acute 
disease, but promote excessive bone formation in chronic conditions of RA, IL-12 may rather 
act early pro-inflammatory, and late anti-inflammatory in arthritis-like diseases (Kinne et al., 
2006; Paunovic et al., 2008). This might explain the negative correlation between these to 
cytokines in the SF from RA patients, where the more studied IL-6 probably reflects late pro-
inflammatory effects, whereas IL-12 may possess anti-inflammatory features. Still, no 
positive correlation between SF IL-12 and IL-6 levels in AS group was found, although both 
cytokines were significantly elevated in correlation to AA precursors in these patients. 
Furthermore, IL-12 is probably more dependent upon other cytokines (Paunovic et al., 2008). 
 
SF IL-12 and serum CRP: There were found no correlations between CRP in serum and IL-12 
in SF. This might be expected as they represent different pathways in inflammation, where 
CRP are primarily related to systemic inflammation and IL-12 may reflect local synovitis and 
development of Th1 pattern. 
 
SF IL-6 and serum CRP: These two inflammatory markers are directly related to each other 
during acute phase response. High levels of IL-6 in SF are expected to leak out into serum and 
increase levels of CRP (Cronstein, 2007). In our study we found significantly positive 
correlations between CRP and IL-6 in SF in SpA group, also contributing to a significant 
correlation between these two inflammatory in all patients. This was not observed in the RA 
patient group, and might be due to a high frequency of medical treatment in RA patients in 
comparison to the SpA group. 
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4.3.3 Fatty acid composition in synovial fluid 
4.3.3.1 Lipids and total fatty acids in all patients 
Lipid class analysis of four random SF sample specimens in this study show that neutral lipid 
content varied between 74-79%, whereas phospholipids varied between 21-26 percent.  The 
TAG contributed to 12% of total lipids in two patients, whereas for two other patients the 
percentage was as high as 18% and 21% (Appendix I). Similar percentage of lipid classes, 
including high total cholesterol levels, were also found in a study carried out by Bole et al 
(Bole, 1962) on SF from RA patients. 
There were observed similar trends in the fatty acid composition both in percentage and 
microgram per gram in all patients. Generally, it was found an extremely low content of fatty 
acids in SF of all patients (1153 g/g, IR 871-1421). This low amount of fatty acids may be 
seen in relation to the also extremely low content of lipids, as well as the high constitution of 
total cholesterol in SF. Bole et al (Bole, 1962) found extremely low content of SF lipids 
constituting highly of cholesterol and cholesterol ester (56.6%), and only 0.73 % of total 
cholesterol contributed to the ester fraction in SF. Still, there are expected to be a 
considerably lower amount of the different lipid classes (including the absence of TAG) in SF 
of healthy individuals (Bole, 1962), which also indicate a lower amount of fatty acids in 
healthy human SF fluid.   
 
4.3.3.2 Rheumatoid Arthritis 
To the best of our knowledge no other studies have quantified fatty acids as absolute values in 
SF. Still, there are a few studies which have quantified the percentage fatty acid profile in SF 
from RA pasients (Navarro et al., 2000; Kim & Cohen, 1966; Sugiyama & Ono, 1966). In this 
study, percentage fatty acid composition of SF from RA patients will be compared to the 
percentage values from the study carried out by Navarro et al (2000), and the results of 
differences between groups will be discussed. It is easier to make a realistic comparison with 
the study carried out by Navarro et al (Navarro et al., 2000), as the study is explained in 
detail, it quantifies single and not sums of fatty acids using a similar one-step method and 
median values.  
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The percentage fatty acid composition in RA patients determined in our study was somewhat 
similar to the analysis done by Navarro et al (2000). Still, there were several differences. In 
our study, there was a lower fraction of SFA, and specifically a lower percentage of 16:0, and 
a higher fraction of PUFA, including noticeably increased percentage of LA. Moreover, ALA, 
marine fatty acids and sum of n-3 PUFA had all duplicated percentage levels. Even though 
low percentage, DPA (22:5n-3) was also identified in our analysis. On the contrary there were 
less n-6 fatty acids included in our fatty acid analysis, including -linolenic acid (18:3n-6) and
docosatetraenoic acid (22:4n-6) in comparison to the analysis carried out by Navarro et al 
(2000). The different fatty acid inclusion may also enhance differences in fatty acid 
composition between the two studies due to compensatory percentage changes. This may also 
give some explanation of the difference in ratio between the studies. In our study the median 
of n-6 to n-3 ratio was at 4.9 (IR 3.6-6.9), which is much lower than Navarro et al (2000), 
estimated roughly to be 9. Generally, the lower ratio in our patients may be influated by 
having less n-6 PUFA and more n-3 fatty acid standards than Navarro et al (2000).  
Another perspective of the differences between the groups may be biological, such as disease 
activity and dietary factors, and pre-analytical methodologies. Both fatty acid analyses were 
performed by similar one-step procedure, but storage conditions was dissimilar. Whereas our 
fatty acids were long-term stored at principally -70ºC, Navarro et al (2000) stored fatty acids 
at -20ºC for unknown period of time, after synovial fluid aspiration to heparinized tubes and 
centrifugation. Whereas the two latter factors was probably completed in our study, and may 
increase the homogenisation of the material, a storage without antioxidant at -20 ºC has 
shown a decrease of PUFA in red blood cell samples from baseline after 17 weeks, and the 
fatty acids have been shown to be unstable in plasma samples for periods of 12 months and 3 
years (Magnusardottir & Skuladottir, 2006; Hodson et al., 2002). Thus, this may indicate a 
possible ongoing oxidation of (in the case of the RBC study, hemolysis may also be an 
important influence on) PUFA and n-3 PUFA in SF contributing to lower levels in the fatty 
acid profile, which was found in RA SF by Navarro et al (2000)  
 
 
4.3.3.3 Group differences 
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There was only found statistically significant differences between the subgroups RA and the 
AS. Also similar tendency of ReA and PsA groups towards AS group contribute to a 
significant difference between SpA and RA groups. AS and SpA groups are significantly 
different from RA in fatty acid composition, which all involve the n-6 and n-3 fatty acids. 
There are significantly higher ratios of n-6 to n-3 fatty acids in µg/g in AS and SpA groups, 
including total n-6 to n-3 ratio, n-6 to vegetable n-3, and n-6 to marine n-3 PUFA. There are 
also more differences found in percentage fatty acids between the groups. Increased levels of 
percentage DHA in SF from the RA group may influence the significantly higher marine n-3 
PUFA and sums of n-3 PUFA, which may additionally influence the significantly lowered 
ratios between n-6 to n-3 PUFA in this group compared with AS and SpA groups. The RA 
group also had significantly higher percentage values of other marine n-3 PUFA (i.e EPA and 
DPA), as well as lower levels of both LA and AA, which may contribute to a significantly 
lower n-6 to n-3 PUFA ratios in both percentage and µg/g. These results indicate that RA 
patients generally have a higher content of n-3 PUFA in their fatty acid composition and 
lower n-6 to n-3 ratios compared to AS and more frequently the SpA. 
 
Disease activity and histopathology in synovial tissue from RA patients have been shown to 
be aggressive, and level of inflammatory activity has been shown to influence the local 
changes, including permeability and angiogenesis of the synovium. This further increases the 
lipid and fatty acid levels entering the synovial fluid, as well as increases lipid peroxidation 
(Basu et al., 2001; Bole, 1962; Navarro et al., 2000; Ropes & Bauer, 1953). 
 
There are uncertainties if fatty acids in SF may reflect diet. Still, an excessive increase of 
lipids and fatty acids are mainly believed to arise from plasma (Prete et al., 1995; Bole, 1962). 
There is also an increase of immune cells in SF from RA patients. The levels are observed to 
increase fivefold, but the increased cell content may be even more extreme (Freemont & 
Denton, 1991). Further,  the fatty acids in the membrane of immune cells have also been 
shown to reflect dietary changes (Calder, 2007). Even though the synovial fluid in these 
patients was obtained in the early nineties and n-3 supplementation was more 
controversial/less establish, the RA patients might have been more familiar to such 
supplementations, and excessive lipids and fatty acids derived from blood may introduce 
higher levels of n-3 PUFA. A possible preservation of n-3 PUFA in SF to protect tissue with 
high inflammatory activity, might also explain higher n-3 PUFA in SF from RA patients in 
comparison to less inflammatory active(painful) AS. 
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Further, even less is known about the lipid and fatty acid pattern of AS and SpA patients. One 
may speculate that these patients have different local inflammation patterns in SF, which 
cause differences in n-3 and n-6 PUFA composition. SpA patients, and specifically AS 
patients, had low frequency of medical treatment in comparison to RA patients, which may 
suggest that these patients have less local inflammation. 
 
4.3.4 Dietary fatty acids and synovial fluid 
There have been few intervention studies regarding the influence of n-6 and n-3 PUFA on 
serum levels of pro-inflammatory cytokines in RA patients, and probably no present studies 
of the SF n-6 and n-3 fatty acid relation to cytokine levels in serum or SF (Sijben & Calder, 
2007; Stamp et al., 2005).  Fish oil studies have demonstrated increased composition of EPA 
and DHA in blood, and enhanced clinical outcomes in patients with rheumatoid arthritis 
(Henderson & Panush, 1999; Cleland et al., 2003; Goldberg & Katz, 2007). Little is known 
about these fatty acids with respect to effects in the actual site of inflammation and joint 
destruction. In our cross-sectional study, there were found significant correlations of n-6 and 
n-3 PUFA levels, and ratios between them, to levels of inflammatory markers in SF in chronic 
inflammatory joint diseases (i.e RA, PsA and AS). Disregarded the possible correlation due to 
excessive lipid entering during inflammation, this may indicate that these n-6 and n-3 PUFA 
interfere with the chronic inflammatory activity in SF in these patients. Thus, an alteration of 
dietary fatty acids introduced to blood might influence fatty acid composition and 
inflammation of SF. 
 
 
4.4 FUTURE REMARKS 
The cross-sectional study described in this thesis indicates that there is an association between 
an increased content of specifically n-6 AA precursor fatty acids and inflammation through 
the IL-6 levels in SF, but little is associated between the SF fatty acids and serum CRP. As for 
the role of IL-12, these n-6 PUFA also show associations to this cytokine. Still, IL-12 might 
not indicate overall inflammation as studies have shown alternate effect in inflamed SF. Thus, 
further studies should be performed on this cytokine in SF before using it as an inflammatory 
marker. 
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In future studies concerning fatty acids in relation to inflammation in SF, it should be 
considered to use percentage values for singular fatty acids  (even though risk for correlation 
of compensatory changes) due to excessive lipids and fatty acids entering the fluid. Thus, in 
this study it was difficult to make any assumptation for each of the specific n-6 and n-3 
PUFA. 
 
Little is known about fatty acids with respect to effects in the actual site of inflammation and 
joint destruction. Later studies should focus on recruiting SF from patients in need of joint 
tap, and use animal models to study the actual effect of the n-6 and n-3 fatty acids on local 
synovial tissue.  Basically, the synovium have marked greater permeability than other tissues, 
and an inflammation of the synovial tissue additionally increases the permeability of the 
synovium, and probably makes the tissue even more exposed to destruction. Even though 
studies implicate that the excessive lipids and fatty acids originates from the blood, more data 
is needed in this area about the specific effect of these substances upon the tissue. 
 
Intervention studies to study the effect of n-3 supplementation on SF are expensive and 
recruiting control groups is ethically difficult as synovial fluid aspirations should be generally 
avoided if it is not necessary, since it might result in an infection. However, such studies 
would provide more certain data on n-6 and n-3 PUFA changes in SF in relation to 
inflammation. Furthermore, a more controlled study is needed, that provide clinical and 
dietary history, and blood and synovial fluid samples in the same manner as Navarro et al 
(2000). Inclusion of cell counting, and analysis of disease marker like cytokines, 
prostaglandins and oxidative stress should also be accomplished. This is important to provide 
a possible association between n-6 and n-3 PUFA and inflammation. More established and 
analytically stable pro-inflammatory markers, such as IL-1	 in synovial fluid should also be 
chosen to provide inflammatory data. However, even though medication may disturb the 
results, stopping medication is ethically unavoidable. 
 
Additionally, it would be interesting to study fatty acids in inflamed synovial tissue of all 
groups within the inflammatory joint diseases, specifically the chronic conditions, since little 
is known about these disease groups and there were found correlations of n-6 and n-3 PUFA 
on inflammation. The apparent difference in n-6 and n-3 PUFA composition of RA patients 
and AS patients seen in this study is of particular interest. 
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Today, it is a great focus on n-3 supplementation and its possible anti-inflammatory effect in 
various diseases. It is important to have in mind that rheumatic diseases, such as RA, PsA, 
ReA and AS, are mostely resulted in genetically susceptible individuals. However, the 
possibility that several enviromental factors, including diet, namely prolonged n-3 
supplementation might hold a preventive effect, and reduce inflammatory mediators in 
synovial tissue and improve clinical outcome must not be ignored. Specially, since the 
medical treatments may give side effects, and is highly expensive. 
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Conclusion 
N-6 and n-3 PUFA in relation to inflammation: We found significant correlations of n-6 and 
n-3 fatty acids to inflammatory markers in the chronic inflammatory diseases; RA, PsA and 
AS, whereas no correlations were found in the acute inflammatory joint disease, ReA, 
suggesting that these fatty acids may influence on chronic inflammation. 
The significant correlations of single and sum of PUFA was of low or moderate magnitude. 
However, the correlation generally did not include the immunomodulatory AA, EPA and 
DHA. Overall, there was a higher frequency of positive correlations of n-6 AA precursor 
PUFA and IL-6 (13 correlations), which indicate that there are a stronger association between 
high levels of n-6 fatty acids and the inflammatory marker IL-6. There was also found 
unexpected positive significant correlations of ALA to IL-6 in several groups, which is a n-3 
PUFA related to less inflammatory features.  
 Significant correlations between the n-6 PUFA and SF IL-12 were found less frequently in 
comparison to SF IL-6. However, the n-6 PUFA correlated negatively to IL-12 in the RA 
group, including DGLA that also correlated positive to IL-6. On the other hand, there was 
found positive correlations of n-6 PUFA and IL-12 in the same manner as the correlations to 
IL-6 in the AS group. In evaluation of n-6 PUFA and inflammation in SF, these findings 
support that IL-12 might possess antagonistic effects, being both anti-inflammatory and 
proinflammatory, whereas n-6 PUFA in correlation to IL-6 give more reliable indications 
about inflammation in SF. 
Between ratios of n-6 to n-3 PUFA and inflammatory markers, only four of totally 72 
correlations were found to be significant. The significant correlations only involved the SpA 
and AS group, three were positive correlations to either CRP or IL-6, and one was negative 
correlation to IL-12. Even though few correlations, they all points to high levels of n-6 to n-3 
ratios represent high levels of inflammation. 
 
Inflammatory disease markers: There are much higher levels of IL-6 than IL-12 in SF in all 
groups, which support its abundance in inflamed SF and its importance in inflammatory 
activity of SF. It may be a better marker to describe inflammatory activity in local synovial 
tissue inflammation than serum CRP and SF IL-12 for all groups. There were no significant 
Conclusion 
   75 
differences, concerning the levels of IL-6 in SF between groups, and the high levels comes 
with a broad range. As for serum CRP, there were found significantly higher levels of serum 
CRP in RA patients and AS versus the PsA group. This is coexistent with literature, which 
find levels of CRP elevated in both RA and AS, whereas PsA patients have lower levels of 
serum CRP due to both lower disease activity and CRP being a less reliable marker of active 
inflammation in this group. There was also a significantly higher level of IL-12 in SF of the 
RA group compared with PsA group and the main group SpA. 
 
No correlation between IL-12 and CRP were found, which might be more expected as they 
represents different inflammatory pathways. Regarding correlations of IL-6 and CRP, a 
significant weakly positive correlation between these inflammatory markers was found, in all 
patients and the SpA, which support the upregulation of serum CRP as a result of high levels 
of SF IL-6. Between the two SF cytokines, levels of IL-12 correlated negatively to levels of 
IL-6 in SF from RA patient groups, which may enhance the theory about its possession of 
chronic late-anti-inflammatory effects. Thus, significantly higher levels of IL-12 found in RA 
patients as compared with PsA group and the SpA, might represent higher anti-inflammatory 
activity, but little can be concluded on levels of disease activity from these associations. 
Fatty acid composition: The fatty acid composition was somewhat similar of that reported in 
the literature (related to RA). However, the SF material and the extreme low amount of lipids, 
which consist highly of cholesterol makes it difficult to quantify the fatty acids. Significantly 
differences were only found between the RA and AS subgroup or more frequently SpA main 
group. All statistically significant differences were seen between the n-6 and n-3 PUFA. The 
RA group had generally higher content of n-3 fatty acids contributing to a lower n-6 to n-3 
ratio. RA patients might have been more familiar to n-3 supplementations, and excessive 
lipids and fatty acids derived from blood may introduce higher levels of n-3 fatty acids, as 
well as different local SF inflammation, are suggestions as reasons for these group 
differences. 
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Appendix 
 
I. LIPID CLASS COMPOSITION OF SYNOVIAL FLUID  
Lipid class composition of four random SF samples one from each of the different 
diagnoses, RA, PsA, ReA and AS. 
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I. LIPID CLASS COMPOSITION OF SYNOVIAL FLUID 
 
Figure A1 presents the average of the percentage lipid composition of SF in patients with 
inflammatory joint diseases. The SF from all four patients as a group contained a high fraction 
of neutral lipids constituting 77 % of total lipids. Based upon this determination, disregarded 
the extremely small values quantified for other phospholipids between the subgroups, there 
was an agreement between lipid classes of the four patients with different diagnosis. Studying 
the main groups, neutral lipid content varied between 74-79%, whereas phospholipids varied 
between 21-26 percent.  The TAG contributed to 12% of total lipids in two patients, whereas 
for two other patients the percentage was as high as 18% and 21%. 
 
Figure A.1: Average percentage lipid class composition in synovial fluid of patients, n=4.  
The bluish pies are different neutral lipid classes, whereas the red and yellowish pies are different 
phospholipids. Other phospholipids include phosphatidylinositol (PI), phosphatidylethanolamine (PE) 
and phosphatidylserine (PS). Abbr; PL: Phospholipids, PC: Phosphatidylcholine, SM: Sphingomyelin, 
NL: Neutral lipids, TAG: Triacylglycerol, FFA: Free fatty acids, CHOL: cholesterol, CE: cholesteryl 
ester. 
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